

1 **Genome-wide association studies of lifetime and frequency cannabis use in 131,895**
2 **individuals**

3
4 Hayley H A Thorpe, PhD¹, Pierre Fontanillas, PhD², John J Meredith, BSc³, Mariela V Jennings,
5 BSc³, Renata B Cupertino, PhD³, Shreya Pakala, BSc³, 23andMe Research Team², Sarah L
6 Elson, PhD², Jibrán Y Khokhar, PhD¹, Lea K Davis^{4,5,6}, PhD, Emma C Johnson, PhD⁷, Abraham
7 A Palmer, PhD^{3,8}, & Sandra Sanchez-Roige, PhD^{3,5,8*}

8
9 ¹Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, Western
10 University, London, ON, Canada.

11 ²23andMe, Inc., Sunnyvale, CA, USA

12 ³Department of Psychiatry, University of California San Diego, La Jolla, CA, USA

13 ⁴Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN,
14 USA

15 ⁵Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

16 ⁶Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center,
17 Nashville, TN, USA

18 ⁷Department of Psychiatry, Washington University School of Medicine, St. Louis, MO USA

19 ⁸Institute for Genomic Medicine, University of California San Diego, La Jolla, CA, USA

20 **Corresponding Author:**

21 Sandra Sanchez-Roige, PhD

22 Department of Psychiatry, University of California San Diego

23 9500 Gilman Drive, La Jolla, CA, USA, 92093

24 Phone: +1-619-874-1426

25 Email: sanchezroige@ucsd.edu

26 **Summary**

27 Cannabis is one of the most widely used drugs globally. Decriminalization of cannabis is further
28 increasing cannabis consumption. We performed genome-wide association studies (**GWASs**) of
29 lifetime ($N=131,895$) and frequency ($N=73,374$) of cannabis use. Lifetime cannabis use GWAS
30 identified two loci, one near *CADM2* (rs11922956, $p=2.40E-11$) and another near *GRM3*
31 (rs12673181, $p=6.90E-09$). Frequency of use GWAS identified one locus near *CADM2*
32 (rs4856591, $p=8.10E-09$; $r^2=0.76$ with rs11922956). Both traits were heritable and genetically
33 correlated with previous GWASs of lifetime use and cannabis use disorder (**CUD**), as well as
34 other substance use and cognitive traits. Polygenic scores (**PGSs**) for lifetime and frequency of
35 cannabis use associated cannabis use phenotypes in *All of Us* participants. Phenome-wide
36 association study of lifetime cannabis use PGS in a hospital cohort replicated associations with
37 substance use and mood disorders, and uncovered associations with celiac and infectious
38 diseases. This work demonstrates the value of GWASs of CUD transition risk factors.

39 **Keywords:** genome-wide association study, cannabis, addiction, genetic correlations, polygenic
40 score, phenome-wide association study, *CADM2*, *GRM3*

41 **Introduction**

42 Approximately 209 million people globally reported using cannabis in 2020¹. The number
43 of people who use cannabis regularly is expected to increase as cannabis is decriminalized in
44 many jurisdictions²⁻⁴. While people report using cannabis for medicinal purposes⁵, there is
45 increasing evidence that cannabis use has short- and long-term adverse consequences across
46 psychiatric, cognitive, and physical health⁶⁻¹⁴. Up to 27% of those who use cannabis in their
47 lifetime are estimated to develop cannabis use disorder (**CUD**)¹⁵, in which cannabis use becomes
48 problematic to an individual's intra- and interpersonal wellbeing¹⁶. However, it is currently unclear
49 what factors contribute most to the development of CUD, and thus of clinical interest to identify
50 what makes an individual vulnerable to cannabis use and its negative effects.

51 Problematic cannabis use is estimated to be 51-78% heritable based on twin studies¹⁷⁻¹⁹
52 and recent genome-wide association studies (**GWASs**) have implicated hundreds of loci
53 associated with CUD²⁰⁻²³. While CUD GWASs are of paramount importance, they come with three
54 major caveats. First, these studies only examine one extreme of the addiction spectrum and
55 neglect other substance-related behaviors and stages between substance initiation to substance
56 use disorder (**SUD**) diagnosis (e.g., recreational use, escalating intake, dependence)²⁴. These
57 pre-addiction phenotypes²⁵ are thought to dictate an individual's progression to SUD²⁶⁻³² and are
58 heritable^{17,26,31,33}. However, aside from GWASs of lifetime cannabis use (having *ever* versus *never*
59 used cannabis in one's lifetime) using data from the International Cannabis Consortium (**ICC**) and
60 other sources^{34,35}, which represents the opposing end of the addiction spectrum to CUD, the
61 genetics of other pre-addiction cannabis traits are understudied^{36,37}. Second, only a portion of
62 those engaging in frequent cannabis use seek treatment or have a CUD diagnosis^{38,39}. It is
63 therefore unlikely that CUD GWASs and downstream analyses fully characterize the genetics of
64 regular, potentially harmful cannabis use and its relationships with physical and mental health.
65 Third, curating case/control SUD GWASs are costly and laborious because they require individual

66 psychological assessments for both cases and controls. Pre-addiction phenotypes can be rapidly
67 and inexpensively collected in large population-based cohorts via self-report questionnaires⁴⁰.

68 We collected data from 23andMe, Inc. research participants by asking if they had ever
69 used cannabis ($N=131,895$). Those who responded yes were asked a follow-up question about
70 the number of days they used cannabis in their heaviest use period ($N=73,374$) as a measure of
71 cannabis use frequency. We performed GWASs of lifetime and frequency of cannabis use,
72 followed by a battery of secondary analyses to compare biological, genetic, and phenotypic
73 associations. Because the frequency of cannabis use phenotype better distinguished between
74 light and heavy use, we hypothesized that the genetics of frequency of cannabis use would more
75 closely resemble CUD compared to lifetime cannabis use genetics.

76

77 **Results**


78 *GWASs of Lifetime Cannabis Use and Frequency of Cannabis Use Uncover Associations with*
79 *CADM2 and GRM3*

80 Participant demographics are described in **Supplementary Table 1**. The cohort was
81 65.2% female with a mean age of 52.8 ± 0.04 years old. Participant responses to surveys about
82 lifetime and frequency of cannabis use are available in **Supplementary Table 2** and
83 **Supplementary Fig. 1**.

84 For single nucleotide polymorphisms (**SNPs**) quality control, see **Supplementary Table**
85 **3**. Genomic control inflation factors for lifetime cannabis use ($\lambda=1.08$) and frequency of cannabis
86 use ($\lambda=1.03$) suggested no substantial inflation due to population stratification for either GWAS.
87 SNP-based heritability (h^2_{SNP}) was $12.88\% \pm 0.97$ for lifetime cannabis use, greater than the h^2_{SNP}
88 for lifetime cannabis use from the ICC ($h^2_{SNP} = 6.63\% \pm 0.43$)³⁴. h^2_{SNP} for frequency of cannabis
89 use was $4.12\% \pm 0.72$ (**Supplementary Table 4**).

90 We identified two genome-wide significant ($p < 5.00E-08$) loci for lifetime cannabis use on
91 chromosomes 3 and 7 (**Fig 1A, Supplementary Fig. 2-3, Supplementary Table 5**). The most
92 significant association was with rs11922956 ($p = 2.40E-11$, chr3p12.1) located upstream the Cell
93 adhesion molecule 2 gene (*CADM2*), replicating findings from previous lifetime use³⁴ and CUD^{22,23}
94 GWASs. *CADM2* encodes a glycoprotein primarily expressed in the brain with functions in cell-
95 cell adhesion, synaptic formation, excitatory neurotransmission, and energy homeostasis^{41,42}. We
96 also found a novel association between lifetime cannabis use and rs12673181 ($p = 6.90E-09$,
97 chr7q21.11), which is a SNP upstream of Metabotropic glutamate receptor 3 gene (*GRM3*)
98 encoding mGlu₃. mGlu₃ is an inhibitory group II receptor affecting a range of intracellular signaling
99 cascades and cellular processes like glutamate neurotransmission and long-term plasticity⁴³.

100 Frequency of cannabis use GWAS identified one significant association with rs4856591
101 ($p=8.10E-09$, chr3p12.1; **Fig1B, Supplementary Fig. 2, 5**), which is near to *CADM2* and is in
102 linkage disequilibrium (LD) with rs11922956 ($r^2=0.76$, $p<1.00E-04$).



103

104 **Figure 1.** Manhattan plots of **A)** lifetime cannabis use ($N=131,895$) and **B)** frequency of cannabis
105 use ($N=73,374$). The horizontal line represents the significance threshold ($p=5.00E-08$). Nearest
106 protein-coding genes (<1Mb) to significant loci (red dots) are labelled. For quantile-quantile plots
107 and locus zoom plots, see **Supplementary Fig. 2-4**.

108 *Secondary Analysis Identifies 40 Lifetime and 4 Frequency of Cannabis Use Genes*

109 Mapping SNPs to genes via gene-based (i.e., **MAGMA**, **H-MAGMA**) and transcriptome-
110 wide association study (**TWAS**; i.e., S-PrediXcan) analyses identified 40 unique genes associated
111 with lifetime cannabis use (**Supplementary Tables 6-8**), and 4 unique genes associated with
112 frequency of cannabis use (**Supplementary Tables 9**). None of the 4 genes associated with
113 frequency of cannabis use (i.e., *MMS22L*, *DSCC1*, *CPSF7*, *RP11-51J9.6*) were implicated in
114 lifetime cannabis use. The only gene to overlap across gene-based and TWAS analyses was
115 *CADM2* (**Supplementary Table 10**). Of the 44 unique genes associated with lifetime and
116 frequency of cannabis use, 29 gene associations have not been previously associated with any
117 cannabis-related trait (**Supplementary Table 10**).



118 Gene-set and tissue-based enrichment analyses yielded no significant results
119 (**Supplementary Tables 11-12**).

120 *Lifetime and Frequency of Cannabis Use Are Genetically Correlated with Psychiatric, Cognitive,*
121 *and Physical Health Traits*

122 There were 115 traits genetically correlated (r_g) with lifetime cannabis use and 38 with
123 frequency of cannabis use after applying a 5% false discovery rate (**FDR**) correction (**Fig. 2-3,**
124 **Supplementary Table 13**). We identified 29 traits that were significantly genetically correlated
125 with both lifetime and frequency of cannabis use (10 anthropomorphic traits; 19 psychiatric traits),
126 which were usually consistent in their direction of effect, with exceptions for intelligence and
127 executive function (positively genetically correlated with frequency of use, negatively genetically
128 correlated with lifetime use), and tense/'highly strung' and delay discounting (negatively
129 genetically correlated with frequency of use, positively genetically correlated with lifetime use), as
130 we review below (**Supplementary Fig. 5**).

131 *Cannabis and Other Substance Use Traits.* The genetic correlation between lifetime and
132 frequency of cannabis use was moderate ($r_g=0.54\pm 0.08$, $p=1.89E-10$), suggesting imperfect

133 genetic overlap between the two traits. We identified positive genetic correlations between CUD
134 and lifetime ($r_g=0.62\pm0.04$, $p=2.44E-59$), as well as frequency of cannabis use ($r_g=0.45\pm0.07$,
135 $p=2.45E-10$; **Fig. 2**). Compared to lifetime cannabis use from the ICC, our lifetime cannabis use
136 trait was more strongly genetically correlated with CUD (23andMe-CUD $r_g=0.62\pm0.04$, $p=2.44E-$
137 59 vs. ICC-CUD $r_g=0.48\pm0.04$, $p=4.30E-33$). Positive genetic correlations with other aspects of
138 substance use (e.g., drug experimentation and lifetime cannabis use: $r_g=0.97\pm0.01$, $p<1.35E-161$;
139 frequency: $r_g=0.54\pm0.07$, $p=5.45E-14$) and misuse (e.g., Alcohol Use Disorder Identification Test
140 (**AUDIT**) problems and lifetime cannabis use: $r_g=0.46\pm0.06$, $p=1.54E-15$; frequency of cannabis
141 use: $r_g=0.30\pm0.10$, $p=2.46E-03$) were among the top genetic correlations for lifetime and
142 frequency of cannabis use (**Fig. 3, Supplementary Table 13**).

A**B**

143

144 **Figure 2.** SNP-based heritability and genetic correlation analysis comparisons across cannabis-related traits. **A)** Genetic correlations
 145 and h_{2SNP} across 23andMe lifetime cannabis use and frequency of cannabis use with ICC lifetime cannabis use³⁴ and CUD from Levey
 146 *et al.*²². $h_{2SNP} \pm$ standard error shown in matrix diagonal (gray boxes), $r_g \pm$ standard error in off-diagonal (white boxes). Correlation
 147 coefficients shown in heatmap color, with p value underneath in black. **B)** CUD requires progression through multiple pre-addiction
 148 stages, including experimental use, regular use, compulsive/harmful use, dependence, cessation attempts, and relapse. Aside from

149 lifetime cannabis use as a proxy for experimental use and frequency of cannabis use as a proxy for regular use, which positively
150 genetically correlate with CUD, most of these stages have not been genetically explored with GWAS.


151 *Psychiatric Disorders.* Lifetime cannabis use was genetically correlated with
152 schizophrenia ($r_g=0.15\pm0.03$, $p=7.33E-07$); however, frequency of cannabis use was not
153 ($r_g=0.02\pm0.05$, $p=0.73$). We also identified associations with other psychiatric traits and lifetime
154 cannabis use like ADHD ($r_g=0.31\pm0.05$, $p=5.20E-12$), depression ($r_g=0.22\pm0.04$, $p=3.52E-10$),
155 and cross-disorder ($r_g=0.30\pm0.05$, $p=3.91E-10$). We identified significant genetic correlations
156 between frequency of cannabis use and the psychiatric-related traits “depression possibly related
157 to stressful or traumatic events” ($r_g=-0.54\pm0.16$, $p=9.22E-04$), stress-related disorder
158 ($r_g=0.33\pm0.10$, $p=1.44E-03$), and anxiety/panic attacks ($r_g=-0.38\pm0.14$, $p=6.06E-03$), though only
159 stress-related disorder was also genetically correlated with lifetime cannabis use ($r_g=0.25\pm0.06$,
160 $p=1.42E-04$).

161 *Externalizing and Risk-Taking Traits.* Among the strongest associations for lifetime
162 cannabis use were positive genetic correlations with externalizing behavior ($r_g=0.84\pm0.03$,
163 $p=5.65E-208$), and two traits that were used to construct externalizing behavior⁴⁴: number of
164 sexual partners ($r_g=0.69\pm0.03$, $p=6.16E-115$) and age at first sex (reverse-coded; $r_g=0.60\pm0.03$,
165 $p=1.08E-83$). We found similar positive genetic correlations with frequency of cannabis use and
166 externalizing and risk-taking (externalizing: $r_g=0.45\pm0.06$, $p=1.68E-15$); number of sexual
167 partners: $r_g=0.42\pm0.06$, $p=3.17E-12$).

168 *Cognitive Traits.* We identified significant genetic correlations between lifetime cannabis
169 use and 11 cognitive and executive function-related traits; these included positive genetic
170 correlations with delay discounting ($r_g=0.16\pm0.04$, $p=3.51E-04$) and other impulsivity-related
171 measures ($r_g=0.27\pm0.05$ to 0.46 ± 0.05 , $p=1.02E-22$ to $3.20E-04$), and negative genetic
172 correlations with childhood intelligence ($r_g=-0.29\pm0.08$, $p=3.20E-04$), educational years ($r_g=-$
173 0.17 ± 0.03 , $p=1.84E-07$), common executive function ($r_g=-0.13\pm0.03$, $p=3.63E-05$), and
174 intelligence ($r_g=-0.12\pm0.03$, $p=3.04E-05$).

175 For frequency of cannabis use, we identified positive genetic correlations with intelligence
176 ($r_g=0.40\pm0.05$, $p=4.18E-14$) and common executive function ($r_g=0.34\pm0.06$, $p=7.86E-09$). There
177 was also a negative genetic correlation with delay discounting ($r_g=-0.23\pm0.07$, $p=1.62E-03$),
178 indicating those who use cannabis more frequently may devalue delayed rewards. Consistent
179 with lifetime cannabis use, we found positive genetic correlation with the impulsivity-related
180 measure perseverance ($r_g=0.28\pm0.09$, $p=1.48E-03$).

181 *Physical Health Traits.* We identified genetic correlations between lifetime cannabis use
182 and 17 physical health traits, including chronic pain ($r_g=0.21\pm0.04$, $p=5.59E-09$), back pain
183 ($r_g=0.22\pm0.05$, $p=2.19E-06$), and coronary artery disease with angina ($r_g=0.17\pm0.04$, $p=2.59E-05$).
184 For frequency of cannabis use, there was a positive genetic correlation with diabetes
185 ($r_g=0.20\pm0.07$, $p=5.96E-03$) and a negative genetic correlation with irritable bowel syndrome ($r_g=-$
186 0.27 ± 0.10 , $p=6.55E-03$).



187

188 **Figure 3.** Comparison of genetic correlations across anthropometric (light gray), health (medium
 189 gray), and psychiatric (dark gray) traits between lifetime cannabis use (lanes 1 and 2) and
 190 frequency of cannabis use (lanes 3 and 4). Lanes 1 and 3 show r_g values calculated by LDSC,
 191 and lanes 2 and 4 show FDR-corrected p values. Only traits for which at least one cohort was
 192 FDR-significant are displayed. For a full list of correlations and trait names, see **Supplementary**
 193 **Table 13.** *reverse coded traits.


194 *Lifetime and Frequency of Cannabis Use Polygenic Scores Associate with Cannabis Use*
195 *Phenotypes*

196 Lifetime and frequency PGS associations with cannabis use traits in *All of Us* (**AoU**) were
197 considered in single (i.e., models only incorporating lifetime *or* frequency of cannabis use PGS
198 as variables) and joint (i.e., models incorporating lifetime *and* frequency of cannabis use PGS as
199 variables) PGS models (**Supplementary Tables 14-16**). In the joint-PGS model simultaneously
200 accounting for lifetime and frequency PGS in the European cohort, based on genetic similarity
201 (see **Methods**), lifetime cannabis use PGS associated with lifetime cannabis use ($\beta=0.19\pm 0.01$,
202 $p<2.00E-16$), daily cannabis use ($\beta=0.09\pm 0.03$, $p=5.09E-04$), and problematic cannabis use
203 ($\beta=0.22\pm 0.02$, $p<2.00E-16$; **Table 1, Supplementary Table 16**). Frequency of cannabis use PGS
204 was associated with lifetime cannabis use ($\beta=0.06\pm 0.01$, $p<2.00E-16$), and nominally associated
205 with problematic cannabis use ($\beta=0.06\pm 0.03$, $p=0.01$), which did not survive multiple testing
206 correction. Lifetime and frequency PGSs were estimated to explain 0.31-1.52% of the phenotypic
207 variance in cannabis use traits (**Fig. 4**). In the African cohort, based on genetic similarity (see
208 **Methods**), lifetime cannabis use was predicted by the lifetime PGS ($\beta=0.08\pm 0.01$, $p=2.76E-12$)
209 and the frequency PGS ($\beta=0.04\pm 0.01$, $p=1.88E-04$), which contributed an estimated 0.20% to
210 phenotypic variance. In both populations, phenotypic variance was primarily attributable to the
211 lifetime cannabis use PGS versus the frequency of cannabis use PGS.

212 In all models, age was a significant negative predictor and being a male was a significant
213 positive predictor of problematic, daily, and lifetime cannabis use (**Supplementary Tables 14-**
214 **17**).

215 **Table 1.** Joint-PGS regression analysis associating lifetime cannabis use PGS, frequency of cannabis use PGS, and select covariates
 216 with lifetime, daily, and problematic cannabis use in AoU cohorts. Bold PGS results are significant following Bonferroni correction
 217 ($p < 8.33E-03$). For full analysis variables, see **Supplementary Table 16**.

Variable	European Cohort									African Cohort								
	Lifetime Use ($N_{\text{case}}=64,711,$ $N_{\text{control}}=49,595$)			Daily Use ($N_{\text{case}}=1,411,$ $N_{\text{control}}=28,112$)			Problematic Use ($N_{\text{case}}=1,825,$ $N_{\text{control}}=118,704$)			Lifetime Use ($N_{\text{case}}=26,064,$ $N_{\text{control}}=21,610$)			Daily Use ($N_{\text{case}}=2,483,$ $N_{\text{control}}=11,718$)			Problematic Use ($N_{\text{case}}=2,315,$ $N_{\text{control}}=50,262$)		
	β	StdErr	p	β	StdErr	p	β	StdErr	p	β	StdErr	p	β	StdErr	p	β	StdErr	p
Lifetime PGS	0.19	0.01	<2.00E-16	0.09	0.03	5.09E-04	0.22	0.02	<2.00E-16	0.08	0.01	2.76E-12	-0.02	0.03	0.52	3.62E-03	0.02	0.88
Frequency PGS	0.06	0.01	<2.00E-16	-0.03	0.03	0.38	0.06	0.03	0.01	0.04	0.01	1.88E-04	0.03	0.03	0.23	0.01	0.03	0.61



218

219 **Figure 4.** Percent proportion of lifetime, daily, and problematic cannabis use variance attributable to lifetime cannabis use PGS,
 220 frequency of cannabis use PGS, or both (joint-PGS) in European and African AoU cohorts. Bonferroni-corrected significance of PGS
 221 contribution for single- and joint-PGS models (see **Table 1, Supplementary Tables 15-16**) shown above data label in its corresponding
 222 legend color (n.s. $p > 0.05$, $*p < 0.05$, $**p < 0.01$, $***p < 0.001$).

223 *Lifetime Cannabis Use Polygenic Score Associates with Psychiatric and Infectious Disease*
224 *Diagnoses*

225 Our phenome- and laboratory-wide association studies (**PheWAS/LabWAS**) uncovered
226 15 FDR-significant PheWAS associations and 9 FDR-significant LabWAS associations with
227 lifetime cannabis use in the BioVU European cohort, as described below (**Fig. 5; Supplementary**
228 **Tables 19-20**). When CUD was included as a covariate, 8 PheWAS and 6 LabWAS associations
229 remained, as we discuss below. Tobacco smoking is prevalent among cannabis users⁴⁵; 4
230 PheWAS and 4 LabWAS associations persisted when adjusting for tobacco use disorder (**TUD**),
231 and 1 PheWAS and 5 LabWAS associations persisted when CUD and TUD were jointly included
232 as covariates, described further below. We found no significant associations with cannabis use
233 frequency in the European cohort, nor any significant associations for lifetime or frequency of
234 cannabis use in the African cohort.

235 *Psychiatric Disorders.* Our PheWAS identified positive associations between lifetime
236 cannabis use PGS and seven psychiatric disorders: TUD ($\beta=0.09\pm0.01$, $p=2.44E-15$), substance
237 addiction and disorders ($\beta=0.14\pm0.02$, $p=8.56E-13$), CUD ($\beta=0.21\pm0.03$, $p=1.24E-10$), alcohol-
238 related disorders ($\beta=0.10\pm0.02$, $p=2.43E-05$), mood disorder ($\beta=0.05\pm0.01$, $p=3.38E-07$), two
239 anxiety traits (anxiety disorders: $\beta=0.05\pm0.01$, $p=8.85E-06$; anxiety disorder: $\beta=0.04\pm0.01$,
240 $p=2.55E-04$), depression ($\beta=0.05\pm0.01$, $p=1.73E-05$), bipolar ($\beta=0.09\pm0.02$, $p=1.59E-04$), and
241 suicide ideation or attempt ($\beta=0.12\pm0.03$, $p=2.64E-04$). TUD, substance addiction and disorders,
242 and mood disorders persisted following adjustment for CUD, only substance addiction and
243 disorders persisted following control for TUD, and no psychiatric disorders were significant
244 following control for both CUD and TUD. We did not find evidence of an association with
245 schizophrenia ($\beta=0.02\pm0.06$, $p=0.68$), schizophrenia and other psychotic disorders ($\beta=0.03\pm0.03$,
246 $p=0.29$), or psychosis ($\beta=0.08\pm0.04$, $p=0.07$).

247 *Infectious Diseases.* We found significant positive associations between lifetime cannabis
248 use and infectious diseases, including human immunodeficiency virus (**HIV**) disease
249 ($\beta=0.21\pm0.04$, $p=1.14E-07$), symptomatic HIV infection ($\beta=0.21\pm0.04$, $p=1.26E-07$), viral hepatitis
250 C ($\beta=0.13\pm0.03$, $p=3.99E-06$), and viral hepatitis ($\beta=0.11\pm0.03$, $p=6.17E-06$). All associations
251 persisted following control for CUD, both HIV associations persisted following control for TUD, but
252 no infectious disease associations persisted following control for both CUD and TUD.


253 *Other Diagnoses.* Lifetime cannabis use PGS was negatively associated with one
254 digestive trait, celiac disease ($\beta=-0.34\pm0.05$, $p=1.55E-11$). This association persisted with
255 following control for CUD, TUD, and combined CUD and TUD.

256 *Blood Laboratory Biomarkers.* LabWAS revealed associations with lifetime cannabis use
257 across four blood biomarkers: mean corpuscular hemoglobin (**MCH**; $\beta=0.02\pm3.53E-03$, $p=1.60E-$
258 07), carbon dioxide serum/plasma ($\beta=-0.02\pm3.47E-03$, $p=1.92E-06$), MCH concentration
259 ($\beta=0.02\pm3.85E-03$, $p=9.41E-05$), and mean corpuscular volume ($\beta=0.01\pm3.53E-03$, $p=7.77E-04$).
260 Following CUD adjustment, all but mean corpuscular volume remained significant; following
261 adjustment for TUD alone or alongside CUD, carbon dioxide serum/plasma and MCH remained
262 significant.

263 *Immune Laboratory Biomarkers.* Two immune biomarkers, leukocytes in blood
264 ($\beta=0.02\pm3.51E-03SE$, $p=2.778E-09$) and complement C4 in serum or plasma ($\beta=0.06\pm0.02$,
265 $p=6.84E-05$), were positively associated with lifetime cannabis use. Both remained significant
266 following control with TUD and CUD independently or together.

267 *Other Laboratory Biomarkers.* The kidney biomarker creatinine in blood ($\beta=-0.02\pm3.90E-$
268 03 , $p=1.02E-04$), endocrine biomarker parathyrin intact in serum or plasma ($\beta=-0.04\pm0.01$,
269 $p=1.25E-03$), and the metabolic biomarker calcitriol in serum and plasma ($\beta=-0.02\pm0.01$,
270 $p=1.37E-03$) were negatively associated with lifetime cannabis use; none were significant

271 following control for TUD, but creatinine in blood remained significant when CUD, and when CUD
272 and TUD were used as covariates.



273

274 **Figure 5.** Forest plot of FDR-significant phenome associations with lifetime cannabis use PGS unconditioned (**UC**), or with adjustment
 275 for cannabis use disorder (**CUD**), tobacco use disorder (**TUD**), or both (**CUD-TUD**). **A)** PheWAS results. **B)** LabWAS results. For full
 276 trait information, see **Supplementary Tables 19-20**.

277 **Discussion**

278 This study contributes to the growing body of cannabis use genetics literature by providing
279 new GWASs of 131,895 individuals of European genetic similarity assessed for lifetime cannabis
280 use and, for the first time, 73,374 individuals assessed for frequency of cannabis use. Both
281 GWASs replicated the robust associations with variants nearby *CADM2* and lifetime cannabis use
282 GWAS identified one novel locus near *GRM3*. We found that lifetime and frequency of cannabis
283 use reliably genetically correlated with substance use-related traits, including CUD, and PGSs for
284 both traits associated with cannabis use phenotypes in AoU. Polygenic analysis of lifetime
285 cannabis use also revealed positive associations with substance use and mood disorders
286 consistent with the literature, and novel phenotypic associations with anxiety disorders, infectious
287 diseases, and red blood cell biomarkers. Overall, these results support the value of cannabis use
288 phenotypes spanning the addiction spectrum in the exploration of genetic factors influencing
289 cannabis use vulnerability and health risk.

290 Pre-addiction phenotypes are intended to capture prodromal symptoms of SUD; lifetime
291 and frequency of cannabis use are heritable risk factors for CUD development^{15,27,29,30,32,34}. They
292 can be easily self-reported in large cohorts, making them attractive targets for GWAS. Lifetime
293 cannabis use captures both experimental/occasional and heavy use; despite the simplicity of this
294 phenotype, we uncovered multiple novel genetic associations with lifetime cannabis use (i.e.,
295 *GRM3* locus, genetic correlations, polygenic associations), and found it reliably associated with
296 CUD and multiple other important traits. Although frequency of use may better account for regular
297 cannabis use, this trait did not associate with CUD to a greater degree compared to lifetime
298 cannabis use ($r_g=0.45\pm0.07$ vs. 0.62 ± 0.04), potentially due to lower power ($N=73,374$ vs.
299 131,895). However, lifetime and frequency of cannabis use was genetically correlated with each
300 other and their associations with other complex traits were almost always directionally consistent.
301 This included positive genetic correlations between lifetime and frequency of use with other

302 substance use, misuse, and behavioral traits thought to be substance use risk factors like
303 externalizing, impulsivity, and risk-taking^{21,44,46-50}, consistent with ICC lifetime cannabis use
304 genetic correlations³⁴ and reports of a general “addiction risk factor” or externalizing factor
305 accounting for genetic overlap across substances^{23,44,51-53}. We previously demonstrated that
306 consumption and problematic use phenotypes (i.e., alcohol^{24,54,55}, tobacco⁵⁶) are correlated but
307 non-identical traits; this is likely true for cannabis. Future multivariate analyses incorporating
308 lifetime, frequency, and other cannabis use GWASs (e.g., CUD, dependence, craving, etc.) could
309 effectively boost locus discovery, identify novel relationships between CUD behaviors and health,
310 and parse genomic factors pertaining to the stages of CUD³⁶, as we and others have previously
311 demonstrated for other substance use traits^{23,54,55,57-59}.

312 One of our most notable findings was a novel association between lifetime cannabis use
313 and rs12673181, which is located upstream of the *GRM3* gene that encodes the group II inhibitory
314 glutamate receptor mGlu₃. There are no known associations with this or other *GRM3* SNPs with
315 cannabis-related traits, and while GWASs implicate *GRM3* variants in other substance use (i.e.,
316 alcohol, smoking)⁶⁰, schizophrenia⁶¹⁻⁶⁵, neuroticism^{66,67}, educational attainment⁶⁸, and other
317 phenotypes⁶⁹⁻⁷¹, these variants are not in LD with rs12673181. Recent studies also suggest that
318 mGlu₃ potentiates activity of mGlu₅⁷², which has also garnered attention for its potential role in
319 addictive-like behaviors and endocannabinoid synthesis^{73,74}. While rs12673181 lies upstream of
320 *GRM3*, it is not a known expression quantitative trait locus (eQTL) of *GRM3* (**Supplementary**
321 **Table 5**)⁷⁵. Further functional work, especially pertaining to the regulation of *GRM3*, is required to
322 characterize its association with cannabis use vulnerability.

323 Through multiple lines of evidence, we found lifetime and frequency of cannabis use
324 associated with the *CADM2* gene, replicating prior GWASs of lifetime cannabis use and CUD^{23,34}.
325 Other GWASs have found an association between SNPs in *CADM2* and other substance use
326 traits^{23,48,51,60,76-91}, risk-taking^{76,85,89,92-94}, impulsivity⁴⁸, and externalizing behaviors⁴⁴.

327 Supporting the genetic correlation observed across cannabis GWAS data, PGSs for
328 lifetime and, to a lesser degree, frequency of cannabis use, associated with phenotypes across
329 the CUD progression spectrum (i.e., lifetime, daily, and problematic use). More variance was
330 explained by lifetime (0.29-1.40%) rather than frequency of use PGS (0.12-0.19%), and together
331 they explained up to 1.6% of phenotypic variance. This is on par with recent substance use PGS
332 analyses⁹⁵⁻⁹⁹, including by Hodgson et al.¹⁰⁰, who estimated that ICC lifetime cannabis use PGS
333 predicted 0.82% of variance in lifetime cannabis use and 1.2% of variance in continued cannabis
334 use in UK Biobank participants. Although it is improbable that cannabis use PGS alone will be
335 sufficient for clinical utility¹⁰¹, lifetime and frequency of cannabis use PGS could be useful for
336 models predicting problematic cannabis use risk.

337 Largely consistent with the genetic correlations we observed, PheWAS uncovered positive
338 associations between lifetime cannabis use PGS with substance use, depression, anxiety,
339 bipolar, and suicidality in the BioVU cohort ($N < 66,917$). To our knowledge, the positive
340 associations with HIV and hepatitis diagnoses, negative association with celiac disease, and
341 mixed associations with multiple blood and immune laboratory biomarkers are novel. Our findings
342 complement a recent PheWAS conducted in the Yale-Penn sample ($N < 10,610$), which is a cohort
343 deeply phenotyped for psychiatric disorder diagnoses and related diagnostic criteria. That study
344 found ICC lifetime cannabis use PGS positively associated with CUD, as well as traits related to
345 other substance use (e.g., alcohol, tobacco, sedatives, stimulants) and depression¹⁰². That many
346 of these relationships disappear when controlling for CUD in our PheWAS and in the Kember *et*
347 *al.*¹⁰² study, as well as when controlling for TUD in our study, supports the hypothesis that these
348 associations are mediated by regular cannabis and tobacco use rather than genetic liability for
349 lifetime cannabis use. Furthermore, like others¹⁰², we found minimal evidence of a relationship
350 between lifetime cannabis use genetics, schizophrenia, and psychosis (aside from bipolar),
351 despite the genetic relationship between cannabis use and psychosis being the subject of intense

352 interest¹⁰³⁻¹⁰⁶ following observations of their apparent bidirectional phenotypic relationship¹⁰⁷.
353 Epidemiological evidence supports a link between cannabis and heavy or high potency cannabis
354 use¹⁰⁸⁻¹¹⁰. Identifying more robust variant associations, especially for frequency of cannabis use,
355 will aid future causal inference analyses that can resolve the role of cannabis genetics in health.

356 Our results were consistent with the prior cannabis use GWAS by ICC³⁴. Lifetime cannabis
357 use measured in US-based 23andMe research participants was genetically correlated with the
358 same trait examined in the ICC cohort, which is composed of participants across North America,
359 Europe, and Australia³⁴. Both lifetime cannabis use datasets were genetically correlated with
360 CUD, but the magnitude of this association was stronger in the 23andMe dataset compared to
361 ICC ($r_g=0.62$ vs. 0.48) despite our smaller sample size. Heritability estimates for our lifetime
362 cannabis use trait was also higher (12.88% vs. 6.63%). Heritability may decrease when meta-
363 analyzing cohorts, possibly due to cohort-specific environmental/geocultural differences that
364 could exist surrounding cannabis use¹¹¹⁻¹¹³. Furthermore, while we found consistent positive
365 correlations with psychiatric disorders, including schizophrenia^{21,34,49}, ADHD^{21,34,47,49}, bipolar
366 disorder^{34,49}, and depression^{21,49} between 23andMe and ICC lifetime cannabis use, we also
367 observed that the genetic correlation with educational attainment was negative with 23andMe and
368 positive with ICC lifetime cannabis use³⁴. Interestingly, while most genetic correlations between
369 lifetime and frequency of cannabis use were also mostly in agreement, lifetime cannabis use
370 negatively genetically correlated with intelligence and common executive function and positively
371 genetically correlated with delay discounting, while we saw the inverse with frequency of use. This
372 is not entirely unprecedented, as relationships between cannabis use and cognitive traits can be
373 paradoxical, especially among those with psychiatric disorders, such as those with psychosis who
374 use cannabis exhibiting greater cognitive abilities than those who do not¹¹⁴. In sum, although most
375 associations were consistent, the differences we observed in trait heritability and patterns of
376 genetic correlations suggest some disunity between 23andMe and ICC lifetime cannabis use

377 cohorts, as well as lifetime and frequency of cannabis use data, which will warrant careful
378 consideration before attempting to meta-analyzing GWAS data.

379 There are several limitations to our study. The legal status of cannabis use differs across
380 countries and even US states and has been changing over the last several decades. Thus, for
381 some of our older subjects, both lifetime and frequency of use could be reflecting use decades
382 ago, whereas others are referencing more recent use. Most studies suggest that legalizing
383 recreational cannabis use increases lifetime and frequency of use rates¹¹⁵, which may have
384 impacted our findings in complex ways that depend on which location a given participant was in
385 at the time of their use. In addition, frequency of cannabis determined by the number of use days
386 over a 30-day window does not accurately reflect lifetime use intensity because it does not
387 account for the duration of regular use or use quantity. These characteristics are important to
388 CUD trajectory and other health and wellbeing relationships¹¹⁶⁻¹¹⁹. Lifetime and frequency of
389 cannabis use GWASs also relied on self-reported data. Cannabis use is most common during
390 adolescence and young adulthood¹²⁰, but participants in this study averaged in their 50s and could
391 have been at greater risk for recall bias regarding cannabis use in early life¹²¹. Socioeconomic
392 variables are also associated with cannabis use rates^{122,123}, and the on-average higher
393 socioeconomic status of 23andMe research participants may have influenced our findings³⁶.
394 Finally, GWASs were conducted using genomic information from individuals of genetically
395 predicted European ancestry. While we extended our polygenic analyses to African cohorts,
396 cross-population transferability of PGS is suboptimal compared to investigations where discovery
397 and target populations are ancestrally aligned^{124,125}. This, along with lower sample numbers, may
398 explain why we observed fewer associations in African versus European cohorts. Due to sample
399 size constraints, we also did not explore associations in other ancestral groups, further limiting
400 the generalizability of our results.

401 This project showcases the utility of pre-addiction phenotypes in cannabis use genomic
402 discovery. Lifetime and frequency of cannabis use genetically associated with CUD and other
403 SUD, alongside concerning health and psychiatric problems. Increasing sample size and
404 investigating other heritable, diverse phenotypes (e.g., drug responsiveness, craving, withdrawal;
405 **Figure 2B**) will be integral to further our understanding of CUD vulnerability and the health
406 consequences of cannabis use.
407

408 **Acknowledgements**

409 We would like to thank the research participants and employees of 23andMe for making
410 this work possible. Participants provided informed consent and volunteered to participate in the
411 research online, under a protocol approved by the external AAHRPP-accredited Institutional
412 Review Board (**IRB**), Ethical & Independent (**E&I**) Review Services. As of 2022, E&I Review
413 Services is part of Salus IRB (<https://www.versiticlinicaltrials.org/salusirb>). The following members
414 of the 23andMe Research Team contributed to this study: Stella Aslibekyan, Adam Auton,
415 Elizabeth Babalola, Robert K. Bell, Jessica Bielenberg, Katarzyna Bryc, Emily Bullis, Daniella
416 Coker, Gabriel Cuellar Partida, Devika Dhamija, Sayantan Das, Teresa Filshtein, Kipper Fletez-
417 Brant, Will Freyman, Karl Heilbron, Pooja M. Gandhi, Karl Heilbron, Barry Hicks, David A. Hinds,
418 Ethan M. Jewett, Yunxuan Jiang, Katelyn Kukar, Keng-Han Lin, Maya Lowe, Jey C. McCreight,
419 Matthew H. McIntyre, Steven J. Micheletti, Meghan E. Moreno, Joanna L. Mountain, Priyanka
420 Nandakumar, Elizabeth S. Noblin, Jared O'Connell, Aaron A. Petrakovitz, G. David Poznik,
421 Morgan Schumacher, Anjali J. Shastri, Janie F. Shelton, Jingchunzi Shi, Suyash Shringarpure,
422 Vinh Tran, Joyce Y. Tung, Xin Wang, Wei Wang, Catherine H. Weldon, Peter Wilton, Alejandro
423 Hernandez, Corinna Wong, Christophe Toukam Tchakouté.

424 We would also like to thank The Externalizing Consortium for sharing the GWAS summary
425 statistics of externalizing. The Externalizing Consortium: Principal Investigators: Danielle M. Dick,
426 Philipp Koellinger, K. Paige Harden, Abraham A. Palmer. Lead Analysts: Richard Karlsson Linnér,
427 Travis T. Mallard, Peter B. Barr, Sandra Sanchez-Roige. Significant Contributors: Irwin D.
428 Waldman. The Externalizing Consortium has been supported by the National Institute on Alcohol
429 Abuse and Alcoholism (R01AA015416 -administrative supplement), and the National Institute on
430 Drug Abuse (R01DA050721). Additional funding for investigator effort has been provided by
431 K02AA018755, U10AA008401, P50AA022537, as well as a European Research Council
432 Consolidator Grant (647648 EdGe to Koellinger). The content is solely the responsibility of the

433 authors and does not necessarily represent the official views of the above funding bodies. The
434 Externalizing Consortium would like to thank the following groups for making the research
435 possible: 23andMe, Add Health, Vanderbilt University Medical Center's BioVU, Collaborative
436 Study on the Genetics of Alcoholism (COGA), the Psychiatric Genomics Consortium's Substance
437 Use Disorders working group, UK10K Consortium, UK Biobank, and Philadelphia
438 Neurodevelopmental Cohort.

439 We gratefully acknowledge *All of Us* participants for their contributions, without whom this
440 research would not have been possible. We also thank the National Institutes of Health's *All of*
441 *Us* Research Program for making available the participant data examined in this study. The *All of*
442 *Us* Research Program is supported by the National Institutes of Health, Office of the Director:
443 Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2
444 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2
445 OD026551; 1 OT2 OD026555; IAA #: AOD 16037; Federally Qualified Health Centers: HHSN
446 263201600085U; Data and Research Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The
447 Participant Center: U24 OD023176; Participant Technology Systems Center: 1 U24 OD023163;
448 Communications and Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and Community
449 Partners: 1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2 OD025276.

450 **Data Availability**

451 We will provide 23andMe summary statistics for the top 10,000 SNPs upon publication.
452 23andMe GWAS summary statistics will be made available through 23andMe to qualified
453 researchers under an agreement with 23andMe that protects the privacy of the 23andMe
454 participants. Please visit <https://research.23andme.com/collaborate/#dataset-access/> for more
455 information and to apply to access the data.

456 We will share the Jupyter notebooks used for PGS analysis in AoU with registered All of
457 Us researchers upon request.

458 **Author Contributions**

459 SSR and AAP conceived the idea. PF and SLE contributed formal analyses and curation
460 of 23andMe data. HHAT contributed to formal analyses, investigation, and data visualization.
461 contributed to formal data analysis and data visualization. JJM, MVJ, RBC, and SP contributed to
462 formal analyses. HHAT and SSR wrote the manuscript. All authors reviewed and edited the
463 manuscript.

464 **Funding Sources**

465 SR is funded through the National Institute on Drug Abuse (NIDA DP1DA054394) and the
466 Tobacco-Related Disease Research Program (T32IR5226). HHAT is funded by a Canadian
467 Institute of Health Research (CIHR) Postdoctoral Fellowship (#491556). JYK is funded by a CIHR
468 Canada Research Chair in Translational Neuropsychopharmacology. PF, the 23andMe Research
469 Team, and SLE are employed by 23andMe, Inc. AAP is supported by NIDA (P50DA037844).

470 **Declaration of Interests**

471 PF, the 23andMe Research Team, and S.L.E. are employed by and hold stock or stock
472 options in 23andMe, Inc. The remaining authors have nothing to disclose.

473

474 **Methods**

475 *Participants and GWASs*

476 Lifetime and frequency of cannabis use GWASs were conducted in male and female 23andMe
477 research participants of European genetic similarity, as previously described⁴⁸. Ancestry falls
478 along a spectrum^{126,127}; individuals were only included in the analysis if they had >97% European
479 genetic similarity (see **Supplementary Methods**), as determined through local ancestry
480 analysis¹²⁸. Participants provided informed consent and volunteered to participate in research
481 online under a protocol approved by the external AAHRPP-accredited Institutional Review Board
482 (**IRB**), Ethical & Independent (**E&I**) Review Services. As of 2022, E&I Review Services is part of
483 Salus IRB (<https://www.versiticlinicaltrials.org/salusirb>). During 4 months in 2015 and 14 months
484 between 2018 to 2020, participants completed a questionnaire surveying a range of personal and
485 behavior characteristics. Included in this survey were questions on lifetime substance use and
486 substance use frequency. Specifically, “Yes” or “No” responses to the question “Have you ever in
487 your life used marijuana?” were collected as a measure of lifetime cannabis use. If participants
488 answered “Yes”, they were prompted to answer the question “How many days did you use
489 marijuana during your heaviest 30 days?” as a measure of frequency of cannabis use.
490 Participants could respond between 0 and 30 days.

491 For lifetime cannabis use and frequency of cannabis use, 23andMe conducted GWASs of
492 up to 33,419,581 imputed genetic variants using linear regression and assuming an additive
493 genetic model. Samples were genotyped on one of five genotyping platforms. The V1 and V2
494 platforms were variants of the Illumina HumanHap550 + BeadChip, including about 25,000
495 custom SNPs selected by 23andMe, with a total of ~560,000 SNPs. The V3 platform was based
496 on the Illumina OmniExpress + BeadChip, with custom content to improve the overlap with our V2
497 array, with a total of ~950,000 SNPs. The V4 platform is a fully custom array, including a lower
498 redundancy subset of V2 and V3 SNPs with additional coverage of lower-frequency coding

499 variation, and ~570,000 SNPs. The v5 platform, in current use, is an Illumina Infinium Global
500 Screening Array (~640,000 variants) supplemented with ~50,000 variants of custom content.
501 Samples that failed to reach 98.5% call rate were excluded from the study. We excluded SNPs of
502 low genotyping quality, including those that failed a Mendelian transmission test in trios or with
503 large allele frequency discrepancies compared to European 1000 Genomes reference data, failed
504 Hardy-Weinberg Equilibrium testing, failed batch effects testing, or had a call rate <90%, as well
505 as SNPs with a minor allele frequency <0.1% and imputed variants with low imputation quality or
506 with evidence of batch effects (**Supplementary Table 3**). Model covariates included age, sex,
507 the first 5 genetic principal components (**PCs**), and indicator variables for genotype platforms (see
508 **Supplementary Methods** for additional details). Unrelated participants categorized as of
509 European ancestry were included in the GWASs (lifetime cannabis use $N=131,895$; frequency of
510 cannabis use $N=73,374$; Durand et al., 2014). For full details on genotyping and GWASs, see
511 **Supplementary Methods**.

512 *Functional annotation and gene-Based Analyses*

513 *Functional annotation.* Using the web-based platform Functional Mapping and Annotation
514 of Genome-Wide Association Studies (**FUMA v1.3.8**), SNPs were annotated based on ANNOVAR
515 categories, Combined Annotation Dependent Depletion scores, RegulomeDB scores, eQTLs,
516 and chromatin state predicted by ChromHMM. Novel SNPs were identified as those not in LD
517 ($r^2 < 0.10$) or within $\pm 1\text{Mb}$ of GWAS-significant SNPs uncovered by other GWASs of cannabis use
518 traits (e.g., initiation, age of onset, CUD) sourced from the literature^{20-23,34,35,51,129-133} and from the
519 EBI GWAS Catalog (<https://www.ebi.ac.uk/gwas/>). Novel genes were identified as those not
520 identified by gene-based analyses in other cannabis-related studies^{22,34,35,103,134-138} or with
521 start/stop positions within $\pm 1\text{Mb}$ of previously uncovered GWAS-significant SNPs.

522 *MAGMA gene-based and pathway analyses.* We used Multi-marker Analysis of GenoMic
523 Annotation (**MAGMA**, v1.08, Ensembl build v92), which is included in FUMA, to annotate SNPs

524 to protein-coding genes. LD was estimated using the 1000 Genomes European reference sample,
525 and significance determined following Bonferroni correction ($p < 2.53E-06$). Gene-set analysis was
526 conducted on 10,678 gene-sets and Gene Ontology terms curated from the Molecular Signatures
527 Database (MsigDB v7.0). Tissue-specific gene expression profiles were assessed in 54 tissue
528 types and 30 general tissue types with average gene expression in each tissue used as a
529 covariate. Using Genome-Tissue Expression (**GTEx**, v8) RNA-seq data, gene expression values
530 were \log_2 transformed from the average Reads Per Kilobase Million (max value=50) per tissue.
531 Significance was determined following Bonferroni correction ($p < 9.26E-04$ for 54 tissue types;
532 $p < 1.67E-03$ for 30 general tissue types).

533 *H-MAGMA*. We incorporated lifetime and frequency of cannabis use GWAS data with
534 chromatin interaction profiles from human brain tissue using Hi-C coupled MAGMA (**H-MAGMA**;
535 Sey et al., 2020). H-MAGMA assigns non-coding SNPs to genes based on chromatin interactions
536 from fetal brain, adult brain, midbrain neurons, cortical neurons, iPSC-derived neurons, and iPSC-
537 derived astrocytes datasets (<https://github.com/thewonlab/H-MAGMA>). Exonic and promoter
538 SNPs were assigned to genes based on physical position¹³⁹. We applied a Bonferroni correction
539 based on the total number of gene-tissue pairs tested ($p < 9.42E-07$ to $9.45E-07$).

540 *S-PrediXcan*. We performed a transcriptome-wide association study using S-PrediXcan
541 (v0.7.5) to identify eQTL-linked genes associated with lifetime and frequency of cannabis use¹⁴⁰.
542 S-PrediXcan uses genetic information to predict gene expression levels in various tissues and
543 tests if eQTLs correlate with lifetime or frequency of cannabis use across 49 bodily tissues
544 ($N_{genes}=1,619$ to $9,949$). S-PrediXcan uses precomputed tissue weights from the GTEx project
545 database (<https://www.gtexportal.org/>) as the reference transcriptome dataset via Elastic net
546 models. As input data, we included summary statistics, transcriptome tissue data, and covariance
547 matrices of the SNPs within each gene model (HapMap SNP set available at the PredictDB Data

548 Repository)¹⁴⁰ from all available tissues. We applied Bonferroni correction for each tissue type
549 ($p < 3.09E-05$ to $5.03E-06$).

550 *LDSC heritability and genetic correlations across health, psychiatric, and anthropomorphic traits*

551 Linkage Disequilibrium Score regression (**LDSC**; <https://github.com/bulik/ldsc>) was used
552 to calculate h^2_{SNP} and genetic correlations¹⁴¹. h^2_{SNP} was calculated from pre-computed LD scores
553 (“eur_w_ld_chr”). r_g were calculated between lifetime or frequency of cannabis use with 292 other
554 traits across 22 health, psychiatric, and lifestyle categories (**Supplementary Methods**). We
555 applied a 5% FDR correction to account for multiple testing.

556 *Polygenic score analyses*

557 *PGS of lifetime, daily, and problematic cannabis use in AoU*. We tested the associations
558 between lifetime or frequency of cannabis use PGSs with cannabis traits available for AoU
559 participants clustering within a European or African genetic ancestry panel (for details, see All of
560 Us Research Program Genomics Investigators¹⁴²). AoU is a diverse health database currently
561 including survey responses, physical measurements, genotyping data, and electronic health
562 records (**EHR**) for over 400,000 individuals living in the United States^{142,143}. Using survey and
563 EHR data, participants were assigned binary identifiers for lifetime cannabis use (concept id:
564 1585636), daily cannabis use among those who reported cannabis use in their lifetime (concept
565 id: 1585650), and problematic cannabis use (concept ids: 434327, 440387, 440996, 433452,
566 437838, 4323639, 4103419, 435231, 434019, 434328; **Supplementary Methods**).

567 We calculated PGSs in male or female participants who had available short-read whole
568 genome sequencing data and applicable cannabis use data. We used the Allele Count/Allele
569 Frequency (**ACAF**) threshold SNP callset curated by AoU, which includes SNPs of MAF > 1% or
570 allele counts over 100 for each ancestral subpopulation. Using PRS-CS “auto” v1.1.0, the SNP
571 set was filtered to biallelic SNPs present in the HapMap3 European ancestry set and SNPs were
572 weighted. Lifetime and frequency of cannabis use PGSs were created from 782,975 weighted

573 SNPs using the allelic-scoring function, *score*, in PLINK (v1.9; Ge et al., 2019). The base R
574 function *glm* was used to fit logistic regression models for each cannabis use trait using PGS(s),
575 as well as the additional covariates of age, sex, and the first 10 global PCs provided by AoU.
576 Models included single PGS models (lifetime or frequency PGS + additional covariates), a joint-
577 PGS model (lifetime PGS + frequency PGS + additional covariates), and a null model (additional
578 covariates only). For the joint-PGS model, Bonferroni correction was applied for two tests (lifetime
579 PGS and frequency PGS) and three outcomes (lifetime, daily, and problematic cannabis use) for
580 a total of $N=6$ comparisons ($p<8.33E-03$); single PGS models were corrected for one test and
581 three outcomes ($N=3$, $p<1.67E-02$). Joint-PGS liability scale R^2 values were calculated as
582 previously described by Lee et al.¹⁴⁵ using the *NagelkerkeR2* function in the R package *fmsb*
583 (v0.7.6) and the estimated prevalence of cannabis use traits in US adults (**Supplementary**
584 **Methods**). PGS ΔR^2 was calculated by subtracting R^2 calculated from models including PGS from
585 the R^2 of the null model.

586 *Phenome- and Laboratory-wide association analyses in a hospital cohort (BioVU)*. We
587 tested associations between lifetime or frequency of cannabis use PGSs and medical condition
588 liability from hospital-based cohorts using data from the Vanderbilt University Medical Center
589 (VUMC; IRB #160302, #172020, #190418)¹⁴⁶. The BioVU cohort, a subset of VUMC biobank
590 participants ($N=72,821$), provided genotyping data and EHR containing clinical data and
591 laboratory-assessed biomarkers^{144,146,147}. For each unrelated European ($N=66,917$) and African
592 ($N=12,383$) BioVU participant based on genetic similarity, we computed lifetime and frequency of
593 cannabis use PGSs using the PRS-CS v1.1.0¹⁴⁴.

594 For PheWAS, we fitted a logistic regression model to each case/control disease
595 phenotypes (“phecodes”) to estimate the log odds of each diagnosis given lifetime cannabis
596 use/frequency of cannabis use PGS, while adjusting for sex, median age of the longitudinal EHR,
597 and the first 10 PCs with the PheWAS v0.12 R package¹⁴⁴. At least two International Disease

598 Classification (**ICD**) codes mapping to a PheWAS disease category (Phecode Map 1.2;
599 <https://phewascatalog.org/phecodes>) and a minimum of 100 cases were required for phecode
600 inclusion. We also conducted additional sensitivity analyses using TUD (phecode 318) and CUD
601 (see **Supplementary Table 12** for CUD ICD codes) as covariates to examine if SUD mediated
602 associations with cannabis PGSs. We calculated the 5% FDR for all associations performed
603 ($N=1,405$).

604 For LabWAS, we implemented the pipeline established by Dennis *et al.*¹⁴⁷. LabWAS
605 associates PGS with laboratory biomarkers (i.e., measurements) evaluated in BioVU participants.
606 LabWAS uses the median, inverse normal quantile transformed age-adjusted values from the
607 QualityLab pipeline in a linear regression to determine the association between lifetime or
608 frequency of cannabis use PGSs with 314 phenotypes. We controlled for the same covariates as
609 for the PheWAS analyses, excluding median age because the pipeline corrects for age using
610 cubic splines with 4 knots. We applied 5% FDR correction across all LabWAS associations
611 performed ($N=314$).

612 All results are presented as the mean \pm standard error unless otherwise specified.

613

614 **References**

- 615 1. United Nations Office on Drug and Crime (2022). Booklet 3 - Drug market trends of
616 Cannabis and Opioids.
- 617 2. Pacek, L.R., Mauro, P.M., and Martins, S.S. (2015). Perceived risk of regular cannabis
618 use in the United States from 2002 to 2012: differences by sex, age, and race/ethnicity.
619 *Drug Alcohol Depend* 149, 232-244. 10.1016/j.drugalcdep.2015.02.009.
- 620 3. Statistics Canada (2013). Mental and substance use disorders in Canada.
- 621 4. Rotermann, M. (2021). Looking back from 2020, how cannabis use and related
622 behaviours changed in Canada. *Health Rep* 32, 3-14. 10.25318/82-003-
623 x202100400001-eng.
- 624 5. Whiting, P.F., Wolff, R.F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A.V.,
625 Keurentjes, J.C., Lang, S., Misso, K., Ryder, S., et al. (2015). Cannabinoids for Medical
626 Use: A Systematic Review and Meta-analysis. *JAMA* 313, 2456-2473.
627 10.1001/jama.2015.6358.
- 628 6. Bellocchio, L., Inchingolo, A.D., Inchingolo, A.M., Lorusso, F., Malcangi, G., Santacroce,
629 L., Scarano, A., Bordea, I.R., Hazballa, D., D'Oria, M.T., et al. (2021). Cannabinoids
630 Drugs and Oral Health-From Recreational Side-Effects to Medicinal Purposes: A
631 Systematic Review. *Int J Mol Sci* 22. 10.3390/ijms22158329.
- 632 7. Diep, C., Tian, C., Vachhani, K., Won, C., Wijeyesundera, D.N., Clarke, H., Singh, M., and
633 Ladha, K.S. (2022). Recent cannabis use and nightly sleep duration in adults: a
634 population analysis of the NHANES from 2005 to 2018. *Reg Anesth Pain Med* 47, 100-
635 104. 10.1136/rapm-2021-103161.
- 636 8. Hasin, D.S., Kerridge, B.T., Saha, T.D., Huang, B., Pickering, R., Smith, S.M., Jung, J.,
637 Zhang, H., and Grant, B.F. (2016). Prevalence and Correlates of DSM-5 Cannabis Use

- 638 Disorder, 2012-2013: Findings from the National Epidemiologic Survey on Alcohol and
639 Related Conditions-III. *Am J Psychiatry* 173, 588-599. 10.1176/appi.ajp.2015.15070907.
- 640 9. Hayley, A.C., Stough, C., and Downey, L.A. (2017). DSM-5 cannabis use disorder,
641 substance use and DSM-5 specific substance-use disorders: Evaluating comorbidity in a
642 population-based sample. *Eur Neuropsychopharmacol* 27, 732-743.
643 10.1016/j.euroneuro.2017.06.004.
- 644 10. Howard, J., and Osborne, J. (2020). Cannabis and work: Need for more research. *Am J*
645 *Ind Med* 63, 963-972. 10.1002/ajim.23170.
- 646 11. Keen, L., 2nd, Turner, A.D., George, L., and Lawrence, K. (2022). Cannabis use
647 disorder severity and sleep quality among undergraduates attending a Historically Black
648 University. *Addict Behav* 134, 107414. 10.1016/j.addbeh.2022.107414.
- 649 12. Lo, J.O., Hedges, J.C., and Girardi, G. (2022). Impact of cannabinoids on pregnancy,
650 reproductive health, and offspring outcomes. *Am J Obstet Gynecol* 227, 571-581.
651 10.1016/j.ajog.2022.05.056.
- 652 13. Pacek, L.R., Herrmann, E.S., Smith, M.T., and Vandrey, R. (2017). Sleep continuity,
653 architecture and quality among treatment-seeking cannabis users: An in-home,
654 unattended polysomnographic study. *Exp Clin Psychopharmacol* 25, 295-302.
655 10.1037/pha0000126.
- 656 14. Page, R.L., 2nd, Allen, L.A., Kloner, R.A., Carriker, C.R., Martel, C., Morris, A.A., Piano,
657 M.R., Rana, J.S., Saucedo, J.F., American Heart Association Clinical Pharmacology, C.,
658 et al. (2020). Medical Marijuana, Recreational Cannabis, and Cardiovascular Health: A
659 Scientific Statement From the American Heart Association. *Circulation* 142, e131-e152.
660 10.1161/CIR.0000000000000883.

- 661 15. Feingold, D., Livne, O., Rehm, J., and Lev-Ran, S. (2020). Probability and correlates of
662 transition from cannabis use to DSM-5 cannabis use disorder: Results from a large-scale
663 nationally representative study. *Drug Alcohol Rev* 39, 142-151. 10.1111/dar.13031.
- 664 16. American Psychiatric Association (2013). Substance-Related and Addictive Disorders. In
665 Diagnostic and Statistical Manual of Mental Disorders, ([https://doi-](https://doi-org.subzero.lib.uoquelp.ca/10.1176/appi.books.9780890425596.dsm16)
666 [org.subzero.lib.uoquelp.ca/10.1176/appi.books.9780890425596.dsm16](https://doi-org.subzero.lib.uoquelp.ca/10.1176/appi.books.9780890425596.dsm16)).
- 667 17. Hines, L.A., Morley, K.I., Rijdsdijk, F., Strang, J., Agrawal, A., Nelson, E.C., Statham, D.,
668 Martin, N.G., and Lynskey, M.T. (2018). Overlap of heritable influences between
669 cannabis use disorder, frequency of use and opportunity to use cannabis: trivariate twin
670 modelling and implications for genetic design. *Psychol Med* 48, 2786-2793.
671 10.1017/S0033291718000478.
- 672 18. Kendler, K.S., Ohlsson, H., Maes, H.H., Sundquist, K., Lichtenstein, P., and Sundquist,
673 J. (2015). A population-based Swedish Twin and Sibling Study of cannabis, stimulant
674 and sedative abuse in men. *Drug Alcohol Depend* 149, 49-54.
675 10.1016/j.drugalcdep.2015.01.016.
- 676 19. Verweij, K.J., Zietsch, B.P., Lynskey, M.T., Medland, S.E., Neale, M.C., Martin, N.G.,
677 Boomsma, D.I., and Vink, J.M. (2010). Genetic and environmental influences on
678 cannabis use initiation and problematic use: a meta-analysis of twin studies. *Addiction*
679 105, 417-430. 10.1111/j.1360-0443.2009.02831.x.
- 680 20. Demontis, D., Rajagopal, V.M., Thorgeirsson, T.E., Als, T.D., Grove, J., Leppala, K.,
681 Gudbjartsson, D.F., Pallesen, J., Hjorthoj, C., Reginsson, G.W., et al. (2019). Genome-
682 wide association study implicates CHRNA2 in cannabis use disorder. *Nat Neurosci* 22,
683 1066-1074. 10.1038/s41593-019-0416-1.
- 684 21. Johnson, E.C., Demontis, D., Thorgeirsson, T.E., Walters, R.K., Polimanti, R., Hatoum,
685 A.S., Sanchez-Roige, S., Paul, S.E., Wendt, F.R., Clarke, T.K., et al. (2020). A large-

- 686 scale genome-wide association study meta-analysis of cannabis use disorder. *Lancet*
687 *Psychiatry* 7, 1032-1045. [10.1016/S2215-0366\(20\)30339-4](https://doi.org/10.1016/S2215-0366(20)30339-4).
- 688 22. Levey, D.F., Galimberti, M., Deak, J.D., Wendt, F.R., Bhattacharya, A., Koller, D.,
689 Harrington, K.M., Quaden, R., Johnson, E.C., Gupta, P., et al. (2023). Multi-ancestry
690 genome-wide association study of cannabis use disorder yields insight into disease
691 biology and public health implications. *Nat Genet* 55, 2094-2103. [10.1038/s41588-023-](https://doi.org/10.1038/s41588-023-01563-z)
692 [01563-z](https://doi.org/10.1038/s41588-023-01563-z).
- 693 23. Xu, H., Toikumo, S., Crist, R.C., Glogowska, K., Jinwala, Z., Deak, J.D., Justice, A.C.,
694 Gelernter, J., Johnson, E.C., Kranzler, H.R., and Kember, R.L. (2023). Identifying
695 genetic loci and phenomic associations of substance use traits: A multi-trait analysis of
696 GWAS (MTAG) study. *Addiction* 118, 1942-1952. [10.1111/add.16229](https://doi.org/10.1111/add.16229).
- 697 24. Sanchez-Roige, S., Palmer, A.A., and Clarke, T.K. (2020). Recent Efforts to Dissect the
698 Genetic Basis of Alcohol Use and Abuse. *Biol Psychiatry* 87, 609-618.
699 [10.1016/j.biopsych.2019.09.011](https://doi.org/10.1016/j.biopsych.2019.09.011).
- 700 25. McLellan, A.T., Koob, G.F., and Volkow, N.D. (2022). Preaddiction-A Missing Concept
701 for Treating Substance Use Disorders. *JAMA Psychiatry* 79, 749-751.
702 [10.1001/jamapsychiatry.2022.1652](https://doi.org/10.1001/jamapsychiatry.2022.1652).
- 703 26. Agrawal, A., Madden, P.A., Bucholz, K.K., Heath, A.C., and Lynskey, M.T. (2014). Initial
704 reactions to tobacco and cannabis smoking: a twin study. *Addiction* 109, 663-671.
705 [10.1111/add.12449](https://doi.org/10.1111/add.12449).
- 706 27. Degenhardt, L., Coffey, C., Carlin, J.B., Swift, W., Moore, E., and Patton, G.C. (2010).
707 Outcomes of occasional cannabis use in adolescence: 10-year follow-up study in
708 Victoria, Australia. *Br J Psychiatry* 196, 290-295. [10.1192/bjp.bp.108.056952](https://doi.org/10.1192/bjp.bp.108.056952).
- 709 28. Scherrer, J.F., Grant, J.D., Duncan, A.E., Sartor, C.E., Haber, J.R., Jacob, T., and
710 Bucholz, K.K. (2009). Subjective effects to cannabis are associated with use, abuse and

- 711 dependence after adjusting for genetic and environmental influences. *Drug Alcohol*
712 *Depend* 105, 76-82. 10.1016/j.drugalcdep.2009.06.014.
- 713 29. Swift, W., Coffey, C., Carlin, J.B., Degenhardt, L., and Patton, G.C. (2008). Adolescent
714 cannabis users at 24 years: trajectories to regular weekly use and dependence in young
715 adulthood. *Addiction* 103, 1361-1370. 10.1111/j.1360-0443.2008.02246.x.
- 716 30. Windle, M., and Wiesner, M. (2004). Trajectories of marijuana use from adolescence to
717 young adulthood: predictors and outcomes. *Dev Psychopathol* 16, 1007-1027.
718 10.1017/s0954579404040118.
- 719 31. Lyons, M.J., Toomey, R., Meyer, J.M., Green, A.I., Eisen, S.A., Goldberg, J., True, W.R.,
720 and Tsuang, M.T. (1997). How do genes influence marijuana use? The role of subjective
721 effects. *Addiction* 92, 409-417.
- 722 32. Leung, J., Chan, G.C.K., Hides, L., and Hall, W.D. (2020). What is the prevalence and
723 risk of cannabis use disorders among people who use cannabis? a systematic review
724 and meta-analysis. *Addict Behav* 109, 106479. 10.1016/j.addbeh.2020.106479.
- 725 33. Haberstick, B.C., Zeiger, J.S., Corley, R.P., Hopper, C.J., Stallings, M.C., Rhee, S.H.,
726 and Hewitt, J.K. (2011). Common and drug-specific genetic influences on subjective
727 effects to alcohol, tobacco and marijuana use. *Addiction* 106, 215-224. 10.1111/j.1360-
728 0443.2010.03129.x.
- 729 34. Pasmán, J.A., Verweij, K.J.H., Gerring, Z., Stringer, S., Sanchez-Roige, S., Treur, J.L.,
730 Abdellaoui, A., Nivard, M.G., Baselmans, B.M.L., Ong, J.S., et al. (2018). GWAS of
731 lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a
732 causal influence of schizophrenia. *Nat Neurosci* 21, 1161-1170. 10.1038/s41593-018-
733 0206-1.
- 734 35. Stringer, S., Minica, C.C., Verweij, K.J., Mbarek, H., Bernard, M., Derringer, J., van Eijk,
735 K.R., Isen, J.D., Loukola, A., Maciejewski, D.F., et al. (2016). Genome-wide association

- 736 study of lifetime cannabis use based on a large meta-analytic sample of 32 330 subjects
737 from the International Cannabis Consortium. *Transl Psychiatry* 6, e769.
738 10.1038/tp.2016.36.
- 739 36. Sanchez-Roige, S., and Palmer, A.A. (2020). Emerging phenotyping strategies will
740 advance our understanding of psychiatric genetics. *Nat Neurosci* 23, 475-480.
741 10.1038/s41593-020-0609-7.
- 742 37. Thorpe, H.H.A., Talhat, M.A., and Khokhar, J.Y. (2021). High genes: Genetic
743 underpinnings of cannabis use phenotypes. *Prog Neuropsychopharmacol Biol*
744 *Psychiatry* 106, 110164. 10.1016/j.pnpbp.2020.110164.
- 745 38. McBain, R.K., Wong, E.C., Breslau, J., Shearer, A.L., Cefalu, M.S., Roth, E., Burnam,
746 M.A., and Collins, R.L. (2020). State medical marijuana laws, cannabis use and
747 cannabis use disorder among adults with elevated psychological distress. *Drug Alcohol*
748 *Depend* 215, 108191. 10.1016/j.drugalcdep.2020.108191.
- 749 39. Hughes, J.R., Naud, S., Budney, A.J., Fingar, J.R., and Callas, P.W. (2016). Attempts to
750 stop or reduce daily cannabis use: An intensive natural history study. *Psychol Addict*
751 *Behav* 30, 389-397. 10.1037/adb0000155.
- 752 40. Mallard, T.T., and Sanchez-Roige, S. (2021). Dimensional Phenotypes in Psychiatric
753 Genetics: Lessons from Genome-Wide Association Studies of Alcohol Use Phenotypes.
754 *Complex Psychiatry* 7, 45-48. 10.1159/000518863.
- 755 41. Fogel, A.I., Akins, M.R., Krupp, A.J., Stagi, M., Stein, V., and Biederer, T. (2007).
756 SynCAMs organize synapses through heterophilic adhesion. *J Neurosci* 27, 12516-
757 12530. 10.1523/JNEUROSCI.2739-07.2007.
- 758 42. Yan, X., Wang, Z., Schmidt, V., Gauert, A., Willnow, T.E., Heinig, M., and Poy, M.N.
759 (2018). *Cadm2* regulates body weight and energy homeostasis in mice. *Mol Metab* 8,
760 180-188. 10.1016/j.molmet.2017.11.010.

- 761 43. Tyler, R.E., Besheer, J., and Joffe, M.E. (2022). Advances in translating mGlu(2) and
762 mGlu(3) receptor selective allosteric modulators as breakthrough treatments for affective
763 disorders and alcohol use disorder. *Pharmacol Biochem Behav* 219, 173450.
764 10.1016/j.pbb.2022.173450.
- 765 44. Karlsson Linner, R., Mallard, T.T., Barr, P.B., Sanchez-Roige, S., Madole, J.W., Driver,
766 M.N., Poore, H.E., de Vlaming, R., Grotzinger, A.D., Tielbeek, J.J., et al. (2021).
767 Multivariate analysis of 1.5 million people identifies genetic associations with traits
768 related to self-regulation and addiction. *Nat Neurosci* 24, 1367-1376. 10.1038/s41593-
769 021-00908-3.
- 770 45. Agrawal, A., Budney, A.J., and Lynskey, M.T. (2012). The co-occurring use and misuse
771 of cannabis and tobacco: a review. *Addiction* 107, 1221-1233. 10.1111/j.1360-
772 0443.2012.03837.x.
- 773 46. Galimberti, M., Levey, D.F., Deak, J.D., Zhou, H., Stein, M.B., and Gelernter, J. (2024).
774 Genetic influences and causal pathways shared between cannabis use disorder and
775 other substance use traits. *Mol Psychiatry*. 10.1038/s41380-024-02548-y.
- 776 47. Poore, H.E., Hatoum, A., Mallard, T.T., Sanchez-Roige, S., Waldman, I.D., Palmer, A.A.,
777 Harden, K.P., Barr, P.B., and Dick, D.M. (2023). A multivariate approach to
778 understanding the genetic overlap between externalizing phenotypes and substance use
779 disorders. *Addict Biol* 28, e13319. 10.1111/adb.13319.
- 780 48. Sanchez-Roige, S., Jennings, M.V., Thorpe, H.H.A., Mallari, J.E., van der Werf, L.C.,
781 Bianchi, S.B., Huang, Y., Lee, C., Mallard, T.T., Barnes, S.A., et al. (2023). *CADM2* is
782 implicated in impulsive personality and numerous other traits by genome- and phenome-
783 wide association studies in humans and mice. *Transl Psychiatry* 13, 167.
784 10.1038/s41398-023-02453-y.

- 785 49. Jang, S.K., Saunders, G., Liu, M., and Me Research, T., Jiang, Y., Liu, D.J., and Vrieze,
786 S. (2022). Genetic correlation, pleiotropy, and causal associations between substance
787 use and psychiatric disorder. *Psychol Med* 52, 968-978. 10.1017/S003329172000272X.
- 788 50. Chang, L.H., Ong, J.S., An, J., Verweij, K.J.H., Vink, J.M., Pasman, J., Liu, M.,
789 MacGregor, S., Cornelis, M.C., Martin, N.G., and Derks, E.M. (2020). Investigating the
790 genetic and causal relationship between initiation or use of alcohol, caffeine, cannabis
791 and nicotine. *Drug Alcohol Depend* 210, 107966. 10.1016/j.drugalcdep.2020.107966.
- 792 51. Hatoum, A.S., Colbert, S.M.C., Johnson, E.C., Huggett, S.B., Deak, J.D., Pathak, G.,
793 Jennings, M.V., Paul, S.E., Karcher, N.R., Hansen, I., et al. (2023). Multivariate genome-
794 wide association meta-analysis of over 1 million subjects identifies loci underlying
795 multiple substance use disorders. *Nat Ment Health* 1, 210-223. 10.1038/s44220-023-
796 00034-y.
- 797 52. Abdellaoui, A., Smit, D.J.A., van den Brink, W., Denys, D., and Verweij, K.J.H. (2021).
798 Genomic relationships across psychiatric disorders including substance use disorders.
799 *Drug Alcohol Depend* 220, 108535. 10.1016/j.drugalcdep.2021.108535.
- 800 53. Waldman, I.D., Poore, H.E., Luningham, J.M., and Yang, J. (2020). Testing structural
801 models of psychopathology at the genomic level. *World Psychiatry* 19, 350-359.
802 10.1002/wps.20772.
- 803 54. Mallard, T.T., Savage, J.E., Johnson, E.C., Huang, Y., Edwards, A.C., Hottenga, J.J.,
804 Grotzinger, A.D., Gustavson, D.E., Jennings, M.V., Anokhin, A., et al. (2022). Item-Level
805 Genome-Wide Association Study of the Alcohol Use Disorders Identification Test in
806 Three Population-Based Cohorts. *Am J Psychiatry* 179, 58-70.
807 10.1176/appi.ajp.2020.20091390.
- 808 55. Kranzler, H.R., Zhou, H., Kember, R.L., Vickers Smith, R., Justice, A.C., Damrauer, S.,
809 Tsao, P.S., Klarin, D., Baras, A., Reid, J., et al. (2019). Genome-wide association study

- 810 of alcohol consumption and use disorder in 274,424 individuals from multiple
811 populations. *Nat Commun* 10, 1499. 10.1038/s41467-019-09480-8.
- 812 56. Toikumo, S., Jennings, M.V., Pham, B.K., Lee, H., Mallard, T.T., Bianchi, S.B., Meredith,
813 J.J., Vilar-Ribo, L., Xu, H., Hatoum, A.S., et al. (2024). Multi-ancestry meta-analysis of
814 tobacco use disorder identifies 461 potential risk genes and reveals associations with
815 multiple health outcomes. *Nature Human Behavior*. 10.1038/s41562-024-01851-6.
- 816 57. Zhou, H., Kember, R.L., Deak, J.D., Xu, H., Toikumo, S., Yuan, K., Lind, P.A.,
817 Farajzadeh, L., Wang, L., Hatoum, A.S., et al. (2023). Multi-ancestry study of the
818 genetics of problematic alcohol use in over 1 million individuals. *Nat Med* 29, 3184-3192.
819 10.1038/s41591-023-02653-5.
- 820 58. Sanchez-Roige, S., Palmer, A.A., Fontanillas, P., Elson, S.L., 23andMe Research Team,
821 Substance Use Disorder Working Group of the Psychiatric Genomics Consortium,
822 Adams, M.J., Howard, D.M., Edenberg, H.J., Davies, G., et al. (2019). Genome-Wide
823 Association Study Meta-Analysis of the Alcohol Use Disorders Identification Test
824 (AUDIT) in Two Population-Based Cohorts. *Am J Psychiatry* 176, 107-118.
825 10.1176/appi.ajp.2018.18040369.
- 826 59. Savage, J.E., Barr, P.B., Phung, T., Lee, Y.H., Zhang, Y., Ge, T., Smoller, J.W., Davis,
827 L.K., Meyers, J., Porjesz, B., et al. (2023). Genetic Heterogeneity Across Dimensions of
828 Alcohol Use Behaviors. *medRxiv*, 2023.2012.2026.23300537.
829 10.1101/2023.12.26.23300537.
- 830 60. Saunders, G.R.B., Wang, X., Chen, F., Jang, S.K., Liu, M., Wang, C., Gao, S., Jiang, Y.,
831 Khunsriraksakul, C., Otto, J.M., et al. (2022). Genetic diversity fuels gene discovery for
832 tobacco and alcohol use. *Nature* 612, 720-724. 10.1038/s41586-022-05477-4.
- 833 61. Trubetskoy, V., Pardinas, A.F., Qi, T., Panagiotaropoulou, G., Awasthi, S., Bigdeli, T.B.,
834 Bryois, J., Chen, C.Y., Dennison, C.A., Hall, L.S., et al. (2022). Mapping genomic loci

- 835 implicates genes and synaptic biology in schizophrenia. *Nature* *604*, 502-508.
836 10.1038/s41586-022-04434-5.
- 837 62. Lam, M., Chen, C.Y., Li, Z., Martin, A.R., Bryois, J., Ma, X., Gaspar, H., Ikeda, M.,
838 Benyamin, B., Brown, B.C., et al. (2019). Comparative genetic architectures of
839 schizophrenia in East Asian and European populations. *Nat Genet* *51*, 1670-1678.
840 10.1038/s41588-019-0512-x.
- 841 63. Pardinas, A.F., Holmans, P., Pocklington, A.J., Escott-Price, V., Ripke, S., Carrera, N.,
842 Legge, S.E., Bishop, S., Cameron, D., Hamshere, M.L., et al. (2018). Common
843 schizophrenia alleles are enriched in mutation-intolerant genes and in regions under
844 strong background selection. *Nat Genet* *50*, 381-389. 10.1038/s41588-018-0059-2.
- 845 64. Li, Z., Chen, J., Yu, H., He, L., Xu, Y., Zhang, D., Yi, Q., Li, C., Li, X., Shen, J., et al.
846 (2017). Genome-wide association analysis identifies 30 new susceptibility loci for
847 schizophrenia. *Nat Genet* *49*, 1576-1583. 10.1038/ng.3973.
- 848 65. Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014).
849 Biological insights from 108 schizophrenia-associated genetic loci. *Nature* *511*, 421-427.
850 10.1038/nature13595.
- 851 66. Nagel, M., Watanabe, K., Stringer, S., Posthuma, D., and van der Sluis, S. (2018). Item-
852 level analyses reveal genetic heterogeneity in neuroticism. *Nat Commun* *9*, 905.
853 10.1038/s41467-018-03242-8.
- 854 67. Luciano, M., Hagenaars, S.P., Davies, G., Hill, W.D., Clarke, T.K., Shirali, M., Harris,
855 S.E., Marioni, R.E., Liewald, D.C., Fawns-Ritchie, C., et al. (2018). Association analysis
856 in over 329,000 individuals identifies 116 independent variants influencing neuroticism.
857 *Nat Genet* *50*, 6-11. 10.1038/s41588-017-0013-8.
- 858 68. Lee, J.J., Wedow, R., Okbay, A., Kong, E., Maghziyan, O., Zacher, M., Nguyen-Viet, T.A.,
859 Bowers, P., Sidorenko, J., Karlsson Linner, R., et al. (2018). Gene discovery and

- 860 polygenic prediction from a genome-wide association study of educational attainment in
861 1.1 million individuals. *Nat Genet* 50, 1112-1121. 10.1038/s41588-018-0147-3.
- 862 69. Hysi, P.G., Choquet, H., Khawaja, A.P., Wojciechowski, R., Tedja, M.S., Yin, J., Simcoe,
863 M.J., Patasova, K., Mahroo, O.A., Thai, K.K., et al. (2020). Meta-analysis of 542,934
864 subjects of European ancestry identifies new genes and mechanisms predisposing to
865 refractive error and myopia. *Nat Genet* 52, 401-407. 10.1038/s41588-020-0599-0.
- 866 70. Tedja, M.S., Wojciechowski, R., Hysi, P.G., Eriksson, N., Furlotte, N.A., Verhoeven,
867 V.J.M., Iglesias, A.I., Meester-Smoor, M.A., Tompson, S.W., Fan, Q., et al. (2018).
868 Genome-wide association meta-analysis highlights light-induced signaling as a driver for
869 refractive error. *Nat Genet* 50, 834-848. 10.1038/s41588-018-0127-7.
- 870 71. Watanabe, K., Jansen, P.R., Savage, J.E., Nandakumar, P., Wang, X., 23andMe
871 Research Team, Hinds, D.A., Gelernter, J., Levey, D.F., Polimanti, R., et al. (2022).
872 Genome-wide meta-analysis of insomnia prioritizes genes associated with metabolic and
873 psychiatric pathways. *Nat Genet* 54, 1125-1132. 10.1038/s41588-022-01124-w.
- 874 72. Di Menna, L., Joffe, M.E., Iacovelli, L., Orlando, R., Lindsley, C.W., Mairesse, J.,
875 Gressens, P., Cannella, M., Caraci, F., Copani, A., et al. (2018). Functional partnership
876 between mGlu3 and mGlu5 metabotropic glutamate receptors in the central nervous
877 system. *Neuropharmacology* 128, 301-313. 10.1016/j.neuropharm.2017.10.026.
- 878 73. Ibrahim, K.S., Abd-Elrahman, K.S., El Mestikawy, S., and Ferguson, S.S.G. (2020).
879 Targeting Vesicular Glutamate Transporter Machinery: Implications on Metabotropic
880 Glutamate Receptor 5 Signaling and Behavior. *Mol Pharmacol* 98, 314-327.
881 10.1124/molpharm.120.000089.
- 882 74. Jung, K.M., Mangieri, R., Stapleton, C., Kim, J., Fegley, D., Wallace, M., Mackie, K., and
883 Piomelli, D. (2005). Stimulation of endocannabinoid formation in brain slice cultures

- 884 through activation of group I metabotropic glutamate receptors. *Mol Pharmacol* 68,
885 1196-1202. 10.1124/mol.105.013961.
- 886 75. The GTEx Consortium (2024). GTEx Portal. <https://gtexportal.org/>.
- 887 76. Schoeler, T., Speed, D., Porcu, E., Pirastu, N., Pingault, J.B., and Kutalik, Z. (2023).
888 Participation bias in the UK Biobank distorts genetic associations and downstream
889 analyses. *Nat Hum Behav* 7, 1216-1227. 10.1038/s41562-023-01579-9.
- 890 77. Deak, J.D., Levey, D.F., Wendt, F.R., Zhou, H., Galimberti, M., Kranzler, H.R., Gaziano,
891 J.M., Stein, M.B., Polimanti, R., Gelernter, J., and Million Veteran, P. (2022). Genome-
892 Wide Investigation of Maximum Habitual Alcohol Intake in US Veterans in Relation to
893 Alcohol Consumption Traits and Alcohol Use Disorder. *JAMA Netw Open* 5, e2238880.
894 10.1001/jamanetworkopen.2022.38880.
- 895 78. Paskan, J.A., Demange, P.A., Guloksuz, S., Willemsen, A.H.M., Abdellaoui, A., Ten
896 Have, M., Hottenga, J.J., Boomsma, D.I., de Geus, E., Bartels, M., et al. (2022). Genetic
897 Risk for Smoking: Disentangling Interplay Between Genes and Socioeconomic Status.
898 *Behav Genet* 52, 92-107. 10.1007/s10519-021-10094-4.
- 899 79. Xu, K., Li, B., McGinnis, K.A., Vickers-Smith, R., Dao, C., Sun, N., Kember, R.L., Zhou,
900 H., Becker, W.C., Gelernter, J., et al. (2020). Genome-wide association study of smoking
901 trajectory and meta-analysis of smoking status in 842,000 individuals. *Nat Commun* 11,
902 5302. 10.1038/s41467-020-18489-3.
- 903 80. Zhou, H., Sealock, J.M., Sanchez-Roige, S., Clarke, T.K., Levey, D.F., Cheng, Z., Li, B.,
904 Polimanti, R., Kember, R.L., Smith, R.V., et al. (2020). Genome-wide meta-analysis of
905 problematic alcohol use in 435,563 individuals yields insights into biology and
906 relationships with other traits. *Nat Neurosci* 23, 809-818. 10.1038/s41593-020-0643-5.
- 907 81. Cai, N., Revez, J.A., Adams, M.J., Andlauer, T.F.M., Breen, G., Byrne, E.M., Clarke,
908 T.K., Forstner, A.J., Grabe, H.J., Hamilton, S.P., et al. (2020). Minimal phenotyping

- 909 yields genome-wide association signals of low specificity for major depression. *Nat*
910 *Genet* 52, 437-447. 10.1038/s41588-020-0594-5.
- 911 82. Evangelou, E., Gao, H., Chu, C., Ntritsos, G., Blakeley, P., Butts, A.R., Pazoki, R.,
912 Suzuki, H., Koskeridis, F., Yiorkas, A.M., et al. (2019). New alcohol-related genes
913 suggest shared genetic mechanisms with neuropsychiatric disorders. *Nat Hum Behav* 3,
914 950-961. 10.1038/s41562-019-0653-z.
- 915 83. Zhong, V.W., Kuang, A., Danning, R.D., Kraft, P., van Dam, R.M., Chasman, D.I., and
916 Cornelis, M.C. (2019). A genome-wide association study of bitter and sweet beverage
917 consumption. *Hum Mol Genet* 28, 2449-2457. 10.1093/hmg/ddz061.
- 918 84. Sanchez-Roige, S., Fontanillas, P., Elson, S.L., Gray, J.C., de Wit, H., MacKillop, J., and
919 Palmer, A.A. (2019). Genome-Wide Association Studies of Impulsive Personality Traits
920 (BIS-11 and UPPS-P) and Drug Experimentation in up to 22,861 Adult Research
921 Participants Identify Loci in the CACNA1I and CADM2 genes. *J Neurosci* 39, 2562-2572.
922 10.1523/JNEUROSCI.2662-18.2019.
- 923 85. Karlsson Linner, R., Biroli, P., Kong, E., Meddens, S.F.W., Wedow, R., Fontana, M.A.,
924 Lebreton, M., Tino, S.P., Abdellaoui, A., Hammerschlag, A.R., et al. (2019). Genome-
925 wide association analyses of risk tolerance and risky behaviors in over 1 million
926 individuals identify hundreds of loci and shared genetic influences. *Nat Genet* 51, 245-
927 257. 10.1038/s41588-018-0309-3.
- 928 86. Liu, M., Jiang, Y., Wedow, R., Li, Y., Brazel, D.M., Chen, F., Datta, G., Davila-Velderrain,
929 J., McGuire, D., Tian, C., et al. (2019). Association studies of up to 1.2 million individuals
930 yield new insights into the genetic etiology of tobacco and alcohol use. *Nat Genet* 51,
931 237-244. 10.1038/s41588-018-0307-5.
- 932 87. Erzurumluoglu, A.M., Liu, M., Jackson, V.E., Barnes, D.R., Datta, G., Melbourne, C.A.,
933 Young, R., Batini, C., Surendran, P., Jiang, T., et al. (2020). Meta-analysis of up to

- 934 622,409 individuals identifies 40 novel smoking behaviour associated genetic loci. *Mol*
935 *Psychiatry* 25, 2392-2409. 10.1038/s41380-018-0313-0.
- 936 88. Kichaev, G., Bhatia, G., Loh, P.R., Gazal, S., Burch, K., Freund, M.K., Schoech, A.,
937 Pasaniuc, B., and Price, A.L. (2019). Leveraging Polygenic Functional Enrichment to
938 Improve GWAS Power. *Am J Hum Genet* 104, 65-75. 10.1016/j.ajhg.2018.11.008.
- 939 89. Clifton, E.A.D., Perry, J.R.B., Imamura, F., Lotta, L.A., Brage, S., Forouhi, N.G., Griffin,
940 S.J., Wareham, N.J., Ong, K.K., and Day, F.R. (2018). Genome-wide association study
941 for risk taking propensity indicates shared pathways with body mass index. *Commun*
942 *Biol* 1, 36. 10.1038/s42003-018-0042-6.
- 943 90. Clarke, T.K., Adams, M.J., Davies, G., Howard, D.M., Hall, L.S., Padmanabhan, S.,
944 Murray, A.D., Smith, B.H., Campbell, A., Hayward, C., et al. (2017). Genome-wide
945 association study of alcohol consumption and genetic overlap with other health-related
946 traits in UK Biobank (N=112 117). *Mol Psychiatry* 22, 1376-1384. 10.1038/mp.2017.153.
- 947 91. Brazel, D.M., Jiang, Y., Hughey, J.M., Turcot, V., Zhan, X., Gong, J., Batini, C.,
948 Weissenkampen, J.D., Liu, M., CHD Exome+ Consortium Consortium for Genetics of
949 Smoking Behaviour, et al. (2019). Exome Chip Meta-analysis Fine Maps Causal
950 Variants and Elucidates the Genetic Architecture of Rare Coding Variants in Smoking
951 and Alcohol Use. *Biol Psychiatry* 85, 946-955. 10.1016/j.biopsych.2018.11.024.
- 952 92. Baselmans, B., Hammerschlag, A.R., Noordijk, S., Ip, H., van der Zee, M., de Geus, E.,
953 Abdellaoui, A., Treur, J.L., and van 't Ent, D. (2022). The Genetic and Neural Substrates
954 of Externalizing Behavior. *Biol Psychiatry Glob Open Sci* 2, 389-399.
955 10.1016/j.bpsgos.2021.09.007.
- 956 93. Strawbridge, R.J., Ward, J., Cullen, B., Tunbridge, E.M., Hartz, S., Bierut, L., Horton, A.,
957 Bailey, M.E.S., Graham, N., Ferguson, A., et al. (2018). Genome-wide analysis of self-

- 958 reported risk-taking behaviour and cross-disorder genetic correlations in the UK Biobank
959 cohort. *Transl Psychiatry* 8, 39. 10.1038/s41398-017-0079-1.
- 960 94. Mills, M.C., Tropf, F.C., Brazel, D.M., van Zuydam, N., Vaez, A., eQTLGen Consortium,
961 Bios Consortium, Human Reproductive Behaviour Consortium, Pers, T.H., Snieder, H.,
962 et al. (2021). Identification of 371 genetic variants for age at first sex and birth linked to
963 externalising behaviour. *Nat Hum Behav* 5, 1717-1730. 10.1038/s41562-021-01135-3.
- 964 95. Johnson, E.C., Sanchez-Roige, S., Acion, L., Adams, M.J., Bucholz, K.K., Chan, G.,
965 Chao, M.J., Chorlian, D.B., Dick, D.M., Edenberg, H.J., et al. (2021). Polygenic
966 contributions to alcohol use and alcohol use disorders across population-based and
967 clinically ascertained samples. *Psychol Med* 51, 1147-1156.
968 10.1017/S0033291719004045.
- 969 96. Sun, Y., Chang, S., Wang, F., Sun, H., Ni, Z., Yue, W., Zhou, H., Gelernter, J., Malison,
970 R.T., Kalayasiri, R., et al. (2019). Genome-wide association study of alcohol
971 dependence in male Han Chinese and cross-ethnic polygenic risk score comparison.
972 *Transl Psychiatry* 9, 249. 10.1038/s41398-019-0586-3.
- 973 97. Lai, D., Wetherill, L., Bertelsen, S., Carey, C.E., Kamarajan, C., Kapoor, M., Meyers,
974 J.L., Anokhin, A.P., Bennett, D.A., Bucholz, K.K., et al. (2019). Genome-wide association
975 studies of alcohol dependence, DSM-IV criterion count and individual criteria. *Genes*
976 *Brain Behav* 18, e12579. 10.1111/gbb.12579.
- 977 98. Chang, L.H., Couvy-Duchesne, B., Liu, M., Medland, S.E., Verhulst, B., Benotsch, E.G.,
978 Hickie, I.B., Martin, N.G., Gillespie, N.A., and GSCAN Consortium (2019). Association
979 between polygenic risk for tobacco or alcohol consumption and liability to licit and illicit
980 substance use in young Australian adults. *Drug Alcohol Depend* 197, 271-279.
981 10.1016/j.drugalcdep.2019.01.015.

- 982 99. Allegrini, A.G., Verweij, K.J.H., Abdellaoui, A., Treur, J.L., Hottenga, J.J., Willemsen, G.,
983 Boomsma, D.I., International Cannabis Consortium, and Vink, J.M. (2019). Genetic
984 Vulnerability for Smoking and Cannabis Use: Associations With E-Cigarette and Water
985 Pipe Use. *Nicotine Tob Res* 21, 723-730. 10.1093/ntr/nty150.
- 986 100. Hodgson, K., Coleman, J.R.I., Hagenaaars, S.P., Purves, K.L., Glanville, K., Choi, S.W.,
987 O'Reilly, P., Breen, G., Major Depressive Disorder Working Group of the Psychiatric
988 Genomics Consortium, and Lewis, C.M. (2020). Cannabis use, depression and self-
989 harm: phenotypic and genetic relationships. *Addiction* 115, 482-492.
990 10.1111/add.14845.
- 991 101. Smeland, O.B., and Andreassen, O.A. (2021). Polygenic risk scores in psychiatry -
992 Large potential but still limited clinical utility. *Eur Neuropsychopharmacol* 51, 68-70.
993 10.1016/j.euroneuro.2021.05.007.
- 994 102. Kember, R.L., Hartwell, E.E., Xu, H., Rotenberg, J., Almasy, L., Zhou, H., Gelernter, J.,
995 and Kranzler, H.R. (2023). Phenome-wide Association Analysis of Substance Use
996 Disorders in a Deeply Phenotyped Sample. *Biol Psychiatry* 93, 536-545.
997 10.1016/j.biopsych.2022.08.010.
- 998 103. Cheng, W., Parker, N., Karadag, N., Koch, E., Hindley, G., Icick, R., Shadrin, A.,
999 O'Connell, K.S., Bjella, T., Bahrami, S., et al. (2023). The relationship between cannabis
1000 use, schizophrenia, and bipolar disorder: a genetically informed study. *Lancet Psychiatry*
1001 10, 441-451. 10.1016/S2215-0366(23)00143-8.
- 1002 104. Johnson, E.C., Hatoum, A.S., Deak, J.D., Polimanti, R., Murray, R.M., Edenberg, H.J.,
1003 Gelernter, J., Di Forti, M., and Agrawal, A. (2021). The relationship between cannabis
1004 and schizophrenia: a genetically informed perspective. *Addiction* 116, 3227-3234.
1005 10.1111/add.15534.

- 1006 105. Reginsson, G.W., Ingason, A., Euesden, J., Bjornsdottir, G., Olafsson, S., Sigurdsson,
1007 E., Oskarsson, H., Tyrfinngsson, T., Runarsdottir, V., Hansdottir, I., et al. (2018).
1008 Polygenic risk scores for schizophrenia and bipolar disorder associate with addiction.
1009 *Addict Biol* 23, 485-492. 10.1111/adb.12496.
- 1010 106. Johnson, E.C., Austin-Zimmerman, I., Thorpe, H.H.A., Levey, D.F., Baranger, D.A.A.,
1011 Colbert, S.M.C., Thorgeirsson, T., Khokhar, J.Y., Davis, L.K., Di Forti, M., et al. (2024).
1012 Dissecting the relationships between tobacco smoking, cannabis use disorder, and
1013 schizophrenia using genomic approaches.
- 1014 107. Hamilton, I., and Monaghan, M. (2019). Cannabis and Psychosis: Are We any Closer to
1015 Understanding the Relationship? *Curr Psychiatry Rep* 21, 48. 10.1007/s11920-019-
1016 1044-x.
- 1017 108. Di Forti, M., Quattrone, D., Freeman, T.P., Tripoli, G., Gayer-Anderson, C., Quigley, H.,
1018 Rodriguez, V., Jongsma, H.E., Ferraro, L., La Cascia, C., et al. (2019). The contribution
1019 of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-
1020 GEI): a multicentre case-control study. *Lancet Psychiatry* 6, 427-436. 10.1016/S2215-
1021 0366(19)30048-3.
- 1022 109. Oluwoye, O., Monroe-DeVita, M., Burduli, E., Chwastiak, L., McPherson, S., McClellan,
1023 J.M., and McDonell, M.G. (2019). Impact of tobacco, alcohol and cannabis use on
1024 treatment outcomes among patients experiencing first episode psychosis: Data from the
1025 national RAISE-ETP study. *Early Interv Psychiatry* 13, 142-146. 10.1111/eip.12542.
- 1026 110. Schoeler, T., Monk, A., Sami, M.B., Klamerus, E., Foglia, E., Brown, R., Camuri, G.,
1027 Altamura, A.C., Murray, R., and Bhattacharyya, S. (2016). Continued versus
1028 discontinued cannabis use in patients with psychosis: a systematic review and meta-
1029 analysis. *Lancet Psychiatry* 3, 215-225. 10.1016/S2215-0366(15)00363-6.

- 1030 111. Durvasula, A., and Price, A.L. (2023). Distinct explanations underlie gene-environment
1031 interactions in the UK Biobank. *medRxiv*. 10.1101/2023.09.22.23295969.
- 1032 112. Abdellaoui, A., Dolan, C.V., Verweij, K.J.H., and Nivard, M.G. (2022). Gene-environment
1033 correlations across geographic regions affect genome-wide association studies. *Nat*
1034 *Genet* 54, 1345-1354. 10.1038/s41588-022-01158-0.
- 1035 113. Thorpe, H.H.A., Fontanillas, P., Pham, B.K., Meredith, J.J., Jennings, M.V., Courchesne-
1036 Krak, N.S., Vilar-Ribó, L., Bianchi, S.B., Mutz, J., 23andMe Research Team, et al.
1037 (2024). Genome-wide association studies of coffee intake in UK/US participants of
1038 European ancestry uncover cohort-specific genetic associations.
1039 *Neuropsychopharmacology*. 10.1038/s41386-024-01870-x.
- 1040 114. Kayir, H., Ruffolo, J., McCunn, P., and Khokhar, J.Y. (2023). The Relationship Between
1041 Cannabis, Cognition, and Schizophrenia: It's Complicated. *Curr Top Behav Neurosci* 63,
1042 437-461. 10.1007/7854_2022_396.
- 1043 115. Farrelly, K.N., Wardell, J.D., Marsden, E., Scarfe, M.L., Najdzionek, P., Turna, J., and
1044 MacKillop, J. (2023). The Impact of Recreational Cannabis Legalization on Cannabis
1045 Use and Associated Outcomes: A Systematic Review. *Subst Abuse* 17,
1046 11782218231172054. 10.1177/11782218231172054.
- 1047 116. Fergusson, D.M., Boden, J.M., and Horwood, L.J. (2015). Psychosocial sequelae of
1048 cannabis use and implications for policy: findings from the Christchurch Health and
1049 Development Study. *Soc Psychiatry Psychiatr Epidemiol* 50, 1317-1326.
1050 10.1007/s00127-015-1070-x.
- 1051 117. van der Pol, P., Liebrechts, N., de Graaf, R., Korf, D.J., van den Brink, W., and van Laar,
1052 M. (2013). Predicting the transition from frequent cannabis use to cannabis dependence:
1053 a three-year prospective study. *Drug Alcohol Depend* 133, 352-359.
1054 10.1016/j.drugalcdep.2013.06.009.

- 1055 118. Walden, N., and Earleywine, M. (2008). How high: quantity as a predictor of cannabis-
1056 related problems. *Harm Reduct J* 5, 20. 10.1186/1477-7517-5-20.
- 1057 119. Zeisser, C., Thompson, K., Stockwell, T., Duff, C., Chow, C., Vallance, K., Ivsins, A.,
1058 Michelow, W., Marsh, D., and Lucas, P. (2012). A 'standard joint'? The role of quantity in
1059 predicting cannabis-related problems. *Addiction Research & Theory* 20, 82-92.
1060 10.3109/16066359.2011.569101.
- 1061 120. Substance Abuse and Mental Health Services Administration (2022). Key substance use
1062 and mental health indicators in the United States: Results from the 2022 National Survey
1063 on Drug Use and Health. Center for Behavioral Health Statistics and Quality, Substance
1064 Abuse and Mental Health Services Administration.
1065 <https://www.samhsa.gov/data/sites/default/files/reports/rpt42731/2022-nsduh-nnr.pdf>.
- 1066 121. Althubaiti, A. (2016). Information bias in health research: definition, pitfalls, and
1067 adjustment methods. *J Multidiscip Healthc* 9, 211-217. 10.2147/JMDH.S104807.
- 1068 122. Jeffers, A.M., Glantz, S., Byers, A., and Keyhani, S. (2021). Sociodemographic
1069 Characteristics Associated With and Prevalence and Frequency of Cannabis Use
1070 Among Adults in the US. *JAMA Netw Open* 4, e2136571.
1071 10.1001/jamanetworkopen.2021.36571.
- 1072 123. Karriker-Jaffe, K.J. (2013). Neighborhood socioeconomic status and substance use by
1073 U.S. adults. *Drug Alcohol Depend* 133, 212-221. 10.1016/j.drugalcdep.2013.04.033.
- 1074 124. Atkinson, E.G., Bianchi, S.B., Ye, G.Y., Martinez-Magana, J.J., Tietz, G.E., Montalvo-
1075 Ortiz, J.L., Giusti-Rodriguez, P., Palmer, A.A., and Sanchez-Roige, S. (2022). Cross-
1076 ancestry genomic research: time to close the gap. *Neuropsychopharmacology* 47, 1737-
1077 1738. 10.1038/s41386-022-01365-7.

- 1078 125. Martin, A.R., Kanai, M., Kamatani, Y., Okada, Y., Neale, B.M., and Daly, M.J. (2019).
1079 Clinical use of current polygenic risk scores may exacerbate health disparities. *Nat*
1080 *Genet* 51, 584-591. 10.1038/s41588-019-0379-x.
- 1081 126. Bryc, K., Durand, E.Y., Macpherson, J.M., Reich, D., and Mountain, J.L. (2015). The
1082 genetic ancestry of African Americans, Latinos, and European Americans across the
1083 United States. *Am J Hum Genet* 96, 37-53. 10.1016/j.ajhg.2014.11.010.
- 1084 127. National Academies of Sciences, Engineering, and Medicine Health and Medicine
1085 Division, Division of Behavioral and Social Sciences and Education, Board on Health
1086 Sciences Policy, Committee on Population, Committee on the Use of Race, and
1087 Ethnicity, and Ancestry as Population Descriptors in Genomics Research (2023). In
1088 Using Population Descriptors in Genetics and Genomics Research: A New Framework
1089 for an Evolving Field. 10.17226/26902.
- 1090 128. Durand, E.Y., Do, C.B., Mountain, J.L., and Macpherson, J.M. (2014). Ancestry
1091 Composition: A Novel, Efficient Pipeline for Ancestry Deconvolution. *bioRxiv*. [Preprint].
1092 10.1101/010512.
- 1093 129. Yin, B., Wang, X., Huang, T., and Jia, J. (2022). Shared Genetics and Causality
1094 Between Decaffeinated Coffee Consumption and Neuropsychiatric Diseases: A Large-
1095 Scale Genome-Wide Cross-Trait Analysis and Mendelian Randomization Analysis. *Front*
1096 *Psychiatry* 13, 910432. 10.3389/fpsyt.2022.910432.
- 1097 130. Agrawal, A., Chou, Y.L., Carey, C.E., Baranger, D.A.A., Zhang, B., Sherva, R., Wetherill,
1098 L., Kapoor, M., Wang, J.C., Bertelsen, S., et al. (2018). Genome-wide association study
1099 identifies a novel locus for cannabis dependence. *Mol Psychiatry* 23, 1293-1302.
1100 10.1038/mp.2017.200.
- 1101 131. Sherva, R., Wang, Q., Kranzler, H., Zhao, H., Koesterer, R., Herman, A., Farrer, L.A.,
1102 and Gelernter, J. (2016). Genome-wide Association Study of Cannabis Dependence

- 1103 Severity, Novel Risk Variants, and Shared Genetic Risks. *JAMA Psychiatry* 73, 472-480.
1104 10.1001/jamapsychiatry.2016.0036.
- 1105 132. Agrawal, A., Lynskey, M.T., Hinrichs, A., Grucza, R., Saccone, S.F., Krueger, R.,
1106 Neuman, R., Howells, W., Fisher, S., Fox, L., et al. (2011). A genome-wide association
1107 study of DSM-IV cannabis dependence. *Addict Biol* 16, 514-518. 10.1111/j.1369-
1108 1600.2010.00255.x.
- 1109 133. Minica, C.C., Dolan, C.V., Hottenga, J.J., Pool, R., Genome of the Netherlands
1110 Consortium, Fedko, I.O., Mbarek, H., Huppertz, C., Bartels, M., Boomsma, D.I., and
1111 Vink, J.M. (2015). Heritability, SNP- and Gene-Based Analyses of Cannabis Use
1112 Initiation and Age at Onset. *Behav Genet* 45, 503-513. 10.1007/s10519-015-9723-9.
- 1113 134. Zhao, Y., Han, X., and Zheng, Z.L. (2023). Analysis of the brain transcriptome for
1114 substance-associated genes: An update on large-scale genome-wide association
1115 studies. *Addict Biol* 28, e13332. 10.1111/adb.13332.
- 1116 135. Greco, L.A., Reay, W.R., Dayas, C.V., and Cairns, M.J. (2023). Exploring opportunities
1117 for drug repurposing and precision medicine in cannabis use disorder using genetics.
1118 *Addict Biol* 28, e13313. 10.1111/adb.13313.
- 1119 136. Carreras-Gallo, N., Dwaraka, V.B., Caceres, A., Smith, R., Mendez, T.L., Went, H., and
1120 Gonzalez, J.R. (2023). Impact of tobacco, alcohol, and marijuana on genome-wide DNA
1121 methylation and its relationship with hypertension. *Epigenetics* 18, 2214392.
1122 10.1080/15592294.2023.2214392.
- 1123 137. Greco, L.A., Reay, W.R., Dayas, C.V., and Cairns, M.J. (2022). Pairwise genetic meta-
1124 analyses between schizophrenia and substance dependence phenotypes reveals novel
1125 association signals with pharmacological significance. *Transl Psychiatry* 12, 403.
1126 10.1038/s41398-022-02186-4.

- 1127 138. Minica, C.C., Verweij, K.J.H., van der Most, P.J., Mbarek, H., Bernard, M., van Eijk, K.R.,
1128 Lind, P.A., Liu, M.Z., Maciejewski, D.F., Palviainen, T., et al. (2018). Genome-wide
1129 association meta-analysis of age at first cannabis use. *Addiction* 113, 2073-2086.
1130 10.1111/add.14368.
- 1131 139. Sey, N.Y.A., Hu, B., Mah, W., Fauni, H., McAfee, J.C., Rajarajan, P., Brennand, K.J.,
1132 Akbarian, S., and Won, H. (2020). A computational tool (H-MAGMA) for improved
1133 prediction of brain-disorder risk genes by incorporating brain chromatin interaction
1134 profiles. *Nat Neurosci* 23, 583-593. 10.1038/s41593-020-0603-0.
- 1135 140. Barbeira, A.N., Dickinson, S.P., Bonazzola, R., Zheng, J., Wheeler, H.E., Torres, J.M.,
1136 Torstenson, E.S., Shah, K.P., Garcia, T., Edwards, T.L., et al. (2018). Exploring the
1137 phenotypic consequences of tissue specific gene expression variation inferred from
1138 GWAS summary statistics. *Nat Commun* 9, 1825. 10.1038/s41467-018-03621-1.
- 1139 141. Bulik-Sullivan, B.K., Loh, P.R., Finucane, H.K., Ripke, S., Yang, J., Schizophrenia
1140 Working Group of the Psychiatric Genomics Consortium, Patterson, N., Daly, M.J.,
1141 Price, A.L., and Neale, B.M. (2015). LD Score regression distinguishes confounding from
1142 polygenicity in genome-wide association studies. *Nat Genet* 47, 291-295.
1143 10.1038/ng.3211.
- 1144 142. All of Us Research Program Genomics Investigators (2024). Genomic data in the All of
1145 Us Research Program. *Nature* 627, 340-346. 10.1038/s41586-023-06957-x.
- 1146 143. All of Us Research Program Investigators, Denny, J.C., Rutter, J.L., Goldstein, D.B.,
1147 Philippakis, A., Smoller, J.W., Jenkins, G., and Dishman, E. (2019). The "All of Us"
1148 Research Program. *N Engl J Med* 381, 668-676. 10.1056/NEJMSr1809937.
- 1149 144. Ge, T., Chen, C.Y., Ni, Y., Feng, Y.A., and Smoller, J.W. (2019). Polygenic prediction via
1150 Bayesian regression and continuous shrinkage priors. *Nat Commun* 10, 1776.
1151 10.1038/s41467-019-09718-5.

- 1152 145. Lee, S.H., Goddard, M.E., Wray, N.R., and Visscher, P.M. (2012). A better coefficient of
1153 determination for genetic profile analysis. *Genet Epidemiol* 36, 214-224.
1154 10.1002/gepi.21614.
- 1155 146. Roden, D.M., Pulley, J.M., Basford, M.A., Bernard, G.R., Clayton, E.W., Balsler, J.R.,
1156 and Masys, D.R. (2008). Development of a large-scale de-identified DNA biobank to
1157 enable personalized medicine. *Clin Pharmacol Ther* 84, 362-369. 10.1038/clpt.2008.89.
- 1158 147. Dennis, J., Sealock, J., Levinson, R.T., Farber-Eger, E., Franco, J., Fong, S., Straub, P.,
1159 Hucks, D., Song, W.L., Linton, M.F., et al. (2021). Genetic risk for major depressive
1160 disorder and loneliness in sex-specific associations with coronary artery disease. *Mol*
1161 *Psychiatry* 26, 4254-4264. 10.1038/s41380-019-0614-y.
- 1162